0001564590-22-008032.txt : 20220301 0001564590-22-008032.hdr.sgml : 20220301 20220301160548 ACCESSION NUMBER: 0001564590-22-008032 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220301 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220301 DATE AS OF CHANGE: 20220301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DermTech, Inc. CENTRAL INDEX KEY: 0001651944 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 842870849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38118 FILM NUMBER: 22697916 BUSINESS ADDRESS: STREET 1: 11099 N. TORREY PINES ROAD STREET 2: SUITE 100 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-450-4222 MAIL ADDRESS: STREET 1: 11099 N. TORREY PINES ROAD STREET 2: SUITE 100 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: Constellation Alpha Capital Corp. DATE OF NAME CHANGE: 20150827 8-K 1 dmtk-8k_20220301.htm 8K - Q4 EARNINGS RELEASE dmtk-8k_20220301.htm
false 0001651944 0001651944 2022-03-01 2022-03-01

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549  

 

FORM 8-K 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1, 2022  

 

DERMTECH, INC.

(Exact name of registrant as specified in its charter)  

 

 

 

 

 

 

Delaware

 

001-38118

 

84-2870849

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

11099 N. Torrey Pines Road, Suite 100

La Jolla, CA 92037

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code (858) 450-4222 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock,
par value $0.0001 per share

DMTK

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   

 


 

Item 2.02.

Results of Operations and Financial Condition.

On March 1, 2022, the Company issued a press release announcing its financial results for the quarter and year ended December 31, 2021 and certain other information. This press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth under this Item 2.02 and in Exhibit 99.1 is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not to be incorporated by reference in any filing of the Company under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

No.

  

Description

 

 

 

99.1

  

Press Release, dated March 1, 2022

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

DERMTECH, INC.

 

 

 

Date: March 1, 2022

 

By:

 

/s/ Kevin Sun

 

 

Name:

 

Kevin Sun

 

 

Title:

 

Chief Financial Officer

 

EX-99.1 2 dmtk-ex991_6.htm EX-99.1 dmtk-ex991_6.htm

 

Exhibit 99.1

 

DermTech Reports Fourth Quarter and Full Year 2021 Financial Results

LA JOLLA, Calif. – March 1, 2022 – DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported financial results as of and for the quarter and fiscal year ended December 31, 2021.

Fourth Quarter and Full Year 2021 Highlights

 

Billable sample volume of approximately 11,780 for the fourth quarter of 2021, a 42% increase compared to approximately 8,300 recorded for the fourth quarter of 2020. Billable sample volume for the full year 2021 of approximately 44,620, an 86% increase compared to 2020.

 

Assay revenue of $3.0 million for the fourth quarter of 2021, a 90% increase compared to the fourth quarter of 2020. Assay revenue for the full year of 2021 of $11.0 million, a 160% increase compared to 2020.

 

Total revenue of $3.2 million for the fourth quarter of 2021, a 49% increase compared to the fourth quarter of 2020. Total revenue for the full year of 2021 of $11.8 million, a 101% increase compared to 2020.

 

Announced agreements with DermatologistOnCall and BioIQ to expand telehealth offerings for the DermTech Melanoma Test.

 

Announced DermTech Stratum, an expanded translational medicine service offering for non-invasive biomarker analysis.

 

Cash, cash equivalents, restricted cash and short-term marketable securities were $228.4 million at the end of the year.

 

“We are pleased with our fourth quarter and full year 2021 performance despite the various headwinds created by the pandemic. In 2021, we substantially scaled our commercial, operations, payor, and development teams. This will enable our ability to capture the promising market opportunities our Smart StickerTM genomics platform addresses,” said John Dobak, MD, chief executive officer of DermTech. “We look forward to making significant progress in 2022, which will be our first year of commercialization with a fully resourced sales and marketing organization.”

 

Fourth Quarter and Full Year 2021 Financial Results

Assay revenue increased $1.4 million, or 90%, to $3.0 million for the three months ended December 31, 2021, compared to $1.6 million for the same period of 2020. Assay revenues grew $6.8 million, or 160%, to $11.0 million for the twelve months ended December 31, 2021, compared to $4.2 million for the same period of 2020. The increase in assay revenue was primarily due to higher billable sample volume and improved average selling price (“ASP”) resulting from better cash collections. Billable sample volume increased 42% to approximately 11,780 for the three months ended December 31, 2021, compared to approximately 8,300 for the same period of 2020. Billable samples increased 86% to approximately 44,620 for the twelve months ended December 31, 2021, compared to approximately 24,000 for the same period


 

of 2020. Contract revenue decreased $0.4 million, or 65%, to $0.2 million for the three months ended December 31, 2021, compared to $0.6 million for the same period of 2020. Contract revenue decreased $0.8 million, or 50%, to $0.8 million for the twelve months ended December 31, 2021, compared to $1.6 million for the same period in 2020. Total revenue increased $1.1 million, or 49%, to $3.2 million for the three months ended December 31, 2021, compared to $2.1 million for the same period of 2020. Total revenue increased $5.9 million, or 101%, to $11.8 million for the twelve months ended December 31, 2021, compared to $5.9 million for the same period of 2020.

Gross margin for the three months ended December 31, 2021, was 4%, compared to 19% for the same period of 2020. The decrease in gross margin for the fourth quarter of 2021 was largely driven by lower contract revenue compared to the same period of the prior year. Gross margin for the twelve months ended December 31, 2021, was 11%, compared to negative 2% for the same period of 2020. The improvement in gross margin for the full year 2021 was largely driven by increased assay revenue in the current period. Assay gross margin for the three months ended December 31, 2021, was negative 1%, compared to negative 9% for the same period of 2020. Assay gross margin for the twelve months ended December 31, 2021, was 5%, compared to negative 38% for the same period of 2020. The increase in assay gross margin was due to higher billable sample volume, improved ASP resulting from better cash collections, and better utilization of current capacity to reduce the per test cost.

Sales and marketing expenses for the three months ended December 31, 2021, were $13.3 million, an increase of 161%, compared to $5.1 million for the same period of 2020. Sales and marketing expenses for the twelve months ended December 31, 2021, were $37.6 million, an increase of 134%, compared to $16.1 million for the same period of 2020. The increase was primarily attributable higher compensation costs related to the expansion of our sales force, marketing, and payor access teams as well as additional marketing and payor infrastructure investments to increase awareness of the DermTech Melanoma Test.

Research and development expenses for the three months ended December 31, 2021, were $6.0 million, an increase of 213%, compared to $1.9 million for the same period of 2020. Research and development expenses for the twelve months ended December 31, 2021, were $16.3 million, an increase of 207%, compared to $5.3 million for the same period of 2020. The increase was due to higher compensation costs of expanding the research and development team, including the addition of a new Chief Scientific Officer and Chief Medical Officer, increased clinical trial costs, increased consulting, software and travel expenses and increased spend on laboratory supplies to support new product development.

General and administrative expenses for the three months ended December 31, 2021, were $7.2 million, an increase of 152%, compared to $2.8 million for the same period of 2020. General and administrative expenses for the twelve months ended December 31, 2021, were $24.8 million, an increase of 80%, compared to $13.8 million for the same period of 2020. The increase was primarily due to higher payroll-related costs and stock-based compensation as we continue to add additional infrastructure such as human resources, billing, information technology and legal resources, among other things.

Net loss for the three months ended December 31, 2021 was $26.1 million, or $0.88 per share, which included $3.8 million of non-cash stock-based compensation, partially offset by a $0.3 million gain related to non-cash change in fair value of warrant liability, compared to a net loss of $10.7 million, or $0.54 per share, for the same period of 2020, which included $1.4 million of non-cash stock-based compensation and a $1.3 million loss related to non-cash change in fair value of warrant liability. Net loss for the twelve months ended December 31, 2021 was $78.3 million, or $2.71 per share, which included $13.4 million of non-cash stock-based compensation and a $1.1 million loss related to non-cash change in fair value of


 

warrant liability, compared to a net loss of $36.5 million, or $2.15 per share, for the same period of 2020, which included $5.0 million of non-cash stock-based compensation and a $1.2 million loss related to non-cash change in fair value of warrant liability.

Cash, cash equivalents, restricted cash and short-term marketable securities totaled $228.4 million as of December 31, 2021.

First Quarter and Full Year 2022 Guidance

Management estimates that first quarter 2022 assay revenue will be between $3.4 million and $3.8 million, and full year 2022 assay revenue will be between $22 million and $26 million.

Conference Call and Webcast Information

DermTech will host a conference call and webcast to discuss the fourth quarter financial results on Tuesday, March 1, 2022 at 1:30 p.m. Pacific time / 4:30 p.m. Eastern time. The conference call can be accessed live over the phone by dialing (844) 467-7114 for U.S. callers or (409) 231-2086 for international callers, using conference ID: 8994008. The live webcast can be accessed at investors.dermtech.com.


 

About DermTech:

DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech developing and marketing novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. For additional information on DermTech, please visit DermTech’s investor relations site at: www.DermTech.com.

 


 

 

Forward-looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations and evaluations with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products and the market opportunity for these products, DermTech’s negotiations with private payors, pilot programs and related efforts, DermTech’s positioning and potential revenue growth, and DermTech’s ability to expand its product offerings and develop pipeline products. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC, including subsequently filed reports. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

 

Contact information

Press and Media:

Sarah Dion

sdion@dermtech.com

(858) 450-4222

 

Investors:

Westwicke Partners

Caroline Corner, PhD  

caroline.corner@westwicke.com

(415) 202-5678


 

DERMTECH, INC.

Consolidated Balance Sheets

(in thousands, except share and per share data)

 

 

 

December 31, 2021

 

 

December 31, 2020

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

176,882

 

 

$

24,248

 

Short-term marketable securities

 

 

48,449

 

 

 

39,529

 

Accounts receivable

 

 

3,847

 

 

 

1,480

 

Inventory

 

 

480

 

 

 

104

 

Prepaid expenses and other current assets

 

 

3,166

 

 

 

1,521

 

Total current assets

 

 

232,824

 

 

 

66,882

 

Property and equipment, net

 

 

4,549

 

 

 

2,731

 

Operating lease right-of-use assets

 

 

7,744

 

 

 

 

Restricted cash

 

 

3,025

 

 

 

 

Other assets

 

 

167

 

 

 

167

 

Total assets

 

$

248,309

 

 

$

69,780

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

2,880

 

 

$

1,573

 

Accrued compensation

 

 

5,120

 

 

 

2,075

 

Accrued liabilities

 

 

1,227

 

 

 

763

 

Short-term deferred revenue

 

 

1,380

 

 

 

905

 

Current portion of operating lease liabilities

 

 

1,453

 

 

 

 

Current portion of finance lease obligations

 

 

121

 

 

 

109

 

Total current liabilities

 

 

12,181

 

 

 

5,425

 

Warrant liability

 

 

146

 

 

 

1,650

 

Long-term deferred revenue

 

 

 

 

 

639

 

Long-term finance lease obligations, less current portion

 

 

136

 

 

 

226

 

Operating lease liabilities, long-term

 

 

6,148

 

 

 

 

Total liabilities

 

 

18,611

 

 

 

7,940

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Common stock, $0.0001 par value per share; 50,000,000

   shares authorized as of December 31, 2021 and 2020;

   29,772,922 and 20,740,413 shares issued and outstanding

   at December 31, 2021 and 2020, respectively

 

 

3

 

 

 

2

 

Additional paid-in capital

 

 

436,183

 

 

 

189,868

 

Accumulated other comprehensive loss

 

 

(124

)

 

 

(1

)

Accumulated deficit

 

 

(206,364

)

 

 

(128,029

)

Total stockholders’ equity

 

 

229,698

 

 

 

61,840

 

Total liabilities and stockholders’ equity

 

$

248,309

 

 

$

69,780

 


 

 

DERMTECH, INC.

Consolidated Statements of Operations

(in thousands, except share and per share data)

 

 

 

 

Three Months Ended December 31,

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assay revenue

 

$

2,969

 

 

$

1,563

 

 

$

11,023

 

 

$

4,241

 

Contract revenue

 

 

196

 

 

 

558

 

 

 

815

 

 

 

1,644

 

Total revenues

 

 

3,165

 

 

 

2,121

 

 

 

11,838

 

 

 

5,885

 

Cost of revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of assay revenue

 

 

3,013

 

 

 

1,698

 

 

 

10,464

 

 

 

5,863

 

Cost of contract revenue

 

 

27

 

 

 

27

 

 

 

100

 

 

 

118

 

Total cost of revenues

 

 

3,040

 

 

 

1,725

 

 

 

10,564

 

 

 

5,981

 

Gross profit/(loss)

 

 

125

 

 

 

396

 

 

 

1,274

 

 

 

(96

)

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

13,330

 

 

 

5,104

 

 

 

37,575

 

 

 

16,077

 

Research and development

 

 

5,990

 

 

 

1,913

 

 

 

16,261

 

 

 

5,293

 

General and administrative

 

 

7,164

 

 

 

2,843

 

 

 

24,836

 

 

 

13,823

 

Total operating expenses

 

 

26,484

 

 

 

9,860

 

 

 

78,672

 

 

 

35,193

 

Loss from operations

 

 

(26,359

)

 

 

(9,464

)

 

 

(77,398

)

 

 

(35,289

)

Other income/(expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income, net

 

 

44

 

 

 

21

 

 

 

151

 

 

 

40

 

Change in fair value of warrant liability

 

 

262

 

 

 

(1,258

)

 

 

(1,088

)

 

 

(1,228

)

Total other expense

 

 

306

 

 

 

(1,237

)

 

 

(937

)

 

 

(1,188

)

Net loss

 

$

(26,053

)

 

$

(10,701

)

 

$

(78,335

)

 

$

(36,477

)

Weighted average shares outstanding used in

    computing net loss per share, basic and diluted

 

 

29,732,059

 

 

 

19,687,908

 

 

 

28,884,874

 

 

 

16,979,411

 

Net loss per share of common stock outstanding,

    basic and diluted

 

$

(0.88

)

 

$

(0.54

)

 

$

(2.71

)

 

$

(2.15

)

 

GRAPHIC 3 gywpz3vs5q1r000001.jpg GRAPHIC begin 644 gywpz3vs5q1r000001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BL'Q5XJM?"6G0WMW!-,DLHB"Q8R#@GN1Z5R M7_"ZM%_Z!NH?DG_Q5:PHU)J\42YQ6C/2Z*\]T[XNZ1J6J6EA%I]\LES,D*LP M3 +, "?FZF;!9:K>0HARJ+,VS_ M +YZ'\JAY>^DAJOW1]345X3I'QAUVR*IJ,4&H1#J2OER?FO'Z5Z9X=^(.@^( MV2&&X-M=MP+>XPK$_P"R>C?@<^UK6AI&I&1U5%%%BNW^SX_S&7MWV/JC_A( M=%_Z#&G_ /@2G^-'_"0Z+_T&-/\ _ E/\:^5Z*/[/C_,'MWV/JC_ (2'1?\ MH,:?_P"!*?XT?\)#HO\ T&-/_P# E/\ &OE>BC^SX_S![=]CZH_X2'1?^@QI M_P#X$I_C1_PD.B_]!C3_ /P)3_&OE>BC^SX_S![=]CZH_P"$AT7_ *#&G_\ M@2G^-'_"0Z+_ -!C3_\ P)3_ !KY7HH_L^/\P>W?8^J/^$AT7_H,:?\ ^!*? MXT?\)#HO_08T_P#\"4_QKY7HH_L^/\P>W?8^J/\ A(=%_P"@QI__ ($I_C6B M"",@Y!Z&OD:OK6V_X]8?]P?RKEQ.'5&UG>YI3GS$M%%%X_&G_ )%:Q_Z_1_Z ]>'5[."_A'+6^(U_"G_(XZ)_V$(/_1BU]1U\ MN>%/^1QT3_L(0?\ HQ:^HZYLP^)%T-F%%%%>>;A1110 4444 %%%% !1110 M4444 %%%% ',?$/_ )$'5_\ KD/_ $(5\V5])_$/_D0=7_ZY#_T(5\V5ZV _ MAOU.:M\04445W&(4444 %%%% !1110 4444 >B^#/BC>Z0\=CK3O=Z?]U93S M)"/K_$/8\^G3%>WVEW;W]I%=6DR302KN21#D,*^2Z[3P!XYF\+7XMKIW?2IV M_>)U\H_WU'\QW^M<.)PBDN:&YM3JVT9]#44R*6.>%)8G5XW4,CJA!]*? M7DG2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !7SM\4O^2AZE_NQ?^BEKZ)JG/I&FW4S37&G6DTK=7D@5F/XD5OAZRI3YFKD M3CS*Q\HT5]4_V!HW_0(L/_ 9/\*/[ T;_H$6'_@,G^%=O]H+^4R]@^Y\K45] M4_V!HW_0(L/_ &3_"C^P-&_Z!%A_P" R?X4?V@OY0]@^Y\K45]4_P!@:-_T M"+#_ ,!D_P *^5JZ,/B%6O96L9SARA117O/PPTG3;OP-:S7.GVDTADD!>2%6 M)^8]R*JO65*/,U<4(\SL>#45]4_V!HW_ $"+#_P&3_"C^P-&_P"@18?^ R?X M5R_V@OY37V#[GRM17U3_ &!HW_0(L/\ P&3_ H_L#1O^@18?^ R?X4?V@OY M0]@^Y\K5]:VW_'K#_N#^54_[ T;_ *!%A_X#)_A6B , 8 KEQ.(5:UE:QI3 MARA1117*:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 >;?&G_D5K'_K]'_H#UX=7N/QI_Y%:Q_Z_1_Z ]>'5[."_A'+6^(U M_"G_ "..B?\ 80@_]&+7U'7RYX4_Y''1/^PA!_Z,6OJ.N;,/B1=#9A1117GF MX4444 %%%% !1110 4444 %%%% !1110!S'Q#_Y$'5_^N0_]"%?-E?2?Q#_Y M$'5_^N0_]"%?-E>M@/X;]3FK?$%%%%=QB>T_#?PGH.K^#H;N_P!,@N+AI9%, MCYR0#QWKK?\ A /"G_0$MOR/^-9?PE_Y$.#_ *[R?^A5W%>'7J35223>YV0B MN5:'-_\ " >%/^@);?D?\:/^$ \*?] 2V_(_XUTE%9^UG_,RN5=CCKKX7>$K ME3MTYH&/\44[C]"2/TKC];^"\D:-+HFH>:0/]1= GZ..,_4#ZU[#15PQ-6+ MT9+IQ?0^4-1TR^TB]>SU"UDM[A.J2#&1ZCU''4<54KZ?\3^%]/\ %.F&TO4 MD7)AG4?/$WJ/;U'?\C7SCKFBWGA_5Y]-O4Q+$>&'1U[,/8UZF'Q*JJW4YYTW M$SJ***Z3,]C^$/BQIHG\.7DF7C4R6C,>J_Q)^'4>V?05ZO7RAIFHSZ3JEMJ% MLVV:WD$B^^.Q]CTKZETZ_AU33;:_MSF&XB61/8$9P?>O(QM+DGS+9G52E=6+ M5%%%<1J%%%% !14<]Q#:P//<2QPPH,M)(P55'N37#:Q\6_#NG,T=H9M0E&1^ MY7:F?]X_S -7"G.;M%7$Y);G>T5XE>?&K5I&'V+3+.!>_FLTA_,%?Y50;XP> M)R<@6(]A"?\ &NA8*JS/VT3WRBO"(OC+XD0C?;:=(.^8G!/Y-70Z=\:[5VVZ MEI$L0_OV\@?]#C^9I2P=9=!JK%GJU%8VB>*]$\0K_P 2V_BEDQDPM\L@_P" MGG\:V:YG%Q=F:)WV"BBBD 445B^)?%%AX5L8KO4$G:.63RE$*ACG!/&O^>&H_P#?E?\ XJC_ (7)X:_YX:C_ -^5_P#BJU^K M5?Y2?:1[GH5%>?Q_&'PW)(J+#J.6( S"O_Q5>@5$ZP45RGB'XAZ M!X==H)K@W-VO!@M@&93[GH/SS[5P%_\ &O4Y'QI^EVL"YZSLTA/Y;'YKZ_C@26.Y M:$"%2 0%4]R>?F-.IAJE./-((U(R=D=917,>)?'FD^%;Z*TU".Z:26/S5,,8 M88R1W(]*Q/\ AA^(-8@TNSBO5N)]VTR1J%^52QR0Q[ TW0JI7<0YX]SL:*1 MF5$9W8*JC)). !7!:]\6="TIWAL5?4IUXS$=L8/^^>OX U$*DD;[-96$$9^Z&5G8?CN _2JR_&#Q.K9*V+>QA/_ ,572L#5,_;1 M/>Z*\8T_XUWZ,!J6DV\RYY:W=HR!]#NS^8KOO#_Q!\/^(G6&"Z-O=-P+>Y&Q MB?8]#^!S64\-5AJT4JD7L=31116!844V21(HVDD=411EF8X 'J37"ZY\6/#^ MELT5H9-1G7(_<<1Y_P!\_P P#5PIRF[15Q.26YWE%>(7GQIUJ23_ $/3K&"/ MTDW2-^8('Z52/Q?\49_Y<1[>0?\ &NA8*JS/VT3WRBO#+?XSZ^D@-Q9:?+'W M"HZD_CN/\JZC2?C-I%TRIJ=E/8L?XT/FH/K@ _H:F6$K1Z#56+/2Z*J:=JEC MJUL+G3[N&YA/\4; X]CZ'V-6ZYVFM&:!1112 **** "BBB@ KY%KZZKY%KTL MN^U\OU.>OT"OH3X4?\B!:?\ 767_ -#-?/=?0GPH_P"1 M/^NLO_ *&:UQ_\ M)>I-'XCMJ***\@Z@HHHH **9++'!$TLLBQQH,L[G ]S7$:S\5_#FELT5L\N MH3#C_1Q\@/\ O'@_AFKA3E-VBKB_G,TI_3;6 MA'X9J98.M'H-58L]/HK/TK7-,URW\_3+V M&Y0==CY- $M%<#K'Q<\/Z<6CLQ-J,HS_JAMCS_O'^8!KC[SXTZQ(_^AZ;90)Z M2EI#^8*_RKHAA:LM;$.I%'MU%>!GXP>)R<@6(]A"?\:GA^,WB)&7S;33I%'4 M>6ZD_CN_I6GU&J3[:)[K17EVF?&G3YG":GID]MDX\R%Q(/J0<$?AFN^T?Q#I M.O0^9IE]#<8&653AU^JGD?E6$Z-2G\2+4XO8TZ***R*"BBB@#S;XT_\ (K6/ M_7Z/_0'KPZOW&]Q]>R_B17G^H_&N\=BNF:3!$H/#W+ER1]%QC\S7-3P]2>J1HYQ6Y[+17 M@C?&'Q.QR%L%]A"?ZM4L7QE\1H5\RVTZ10>3_T*NXKA_A+ M_P B'!_UWD_]"KN*\"O_ !9>IVP^%!1116104444 %>??%GPVNJ>'?[5@CS= MZ>-QP.6B/WA^'WO8 UZ#4<\$5U;RV\Z!XI4*.AZ,I&"/RJZQFPHST M1^1^NZO":]'^#5\8/%5S:$_)(=85 MQ_C+X@Z?X50VR 76I,N5@4\)GH7/;Z=3[=:H_$7Q\/#<']FZ:ZMJLJY+=1;J M>Y_VCV'XGMGP:662>5Y97:21V+.[G)8GJ2>YKNPV$Y_?GL8U*EM$:NO>)]6\ M27/G:E=,Z@Y2%>(T^B_UZUCT45ZL8J*LCF;;W"BBBF 4444 .CD>*19(W9'4 MY5E."#[&O3/"/Q9N[%X[/Q 6NK4\"Z S+'_O?WA^OUZ5YC16=2E"HK2149.+ MT/K2UNH+VUCN;69)H)5W)(AR&%35\[^ O'$_A:_%O<.TFE3-^]CZ^6?[Z^_J M.X_"OH6&:*X@CGAD62*10Z.IR&!Y!!]*\:O0=&5GL=4)J2'UYK\:?^18L/\ MK\'_ * U>E5YK\:?^18L/^OP?^@-1AOXL0J?"SP^BBBO=.,FM?\ C\@_ZZ+_ M #KTSQ_\3);J:72=!GV6JDI-=QGF4]PA[+[CKVXZ^6T5G.E&%5[K\&/^1.NO\ K_?_ -%QUR8[^$:T?B.5 M^-/_ ",]A_UYC_T-J\TKTOXT_P#(SV'_ %YC_P!#:O-*TPO\&)-3XF%=/\/; MVVTWQO87MY,L-O"LSR.W0#R7_P XKF**VG'FBX]R4[.YV7C7X@7WBBX>W@9[ M;2E/R0@X,G^T_K].@_6N-HHI0A&"Y8@VV[L****H04444 >D^"/BA8=2IX8>A'0CV->[>!OB%:^*4%G=!+;557/E@_+,!U*>_J M/Y\X^>ZEM[B:TN8[BWD:*:)@Z.IP5(Z$5A7P\:JUW+A-Q9]:T5S7@CQ5'XKT M%+D[4O(CY=S&IZ-_>'L>H_$0=05R_B[QQIOA.WVRG[1?.,QVJ-SCU8_P (_GV[U!X\ M\;0>$]/$<6V74[A3Y$1Z(.F]O;T'<_0X^>[R\N=0O);N[F>:XE;<\CGDFNW# M87VGO2V,JE3ET1K>(O%^L>)YRU_D:AK5V+7 M3;26YF/9!P/Y\V/_P"(K"6,HIVN6J4F>%45[+J'P3LW!.FZO/$0 M.%N8Q)D_5=N!^!KS_P 0^ ]>\-AI;NU$MJ/^7FW.]!]>Z_B!54\32F[)B=.2 MW,*SOKK3KI+FRN);>=/NR1L5(_*O7?!OQ92Z>.P\1E(I3PEZ!M1C_MCHOU'' MTZUXU155:,*JM(49N.Q]<@@@$'(/0TM>*?#7X@M82PZ%J\N;-SLMIW/^I/96 M/]WT/;Z=/:Z\6M1E2ERLZXR4E=!111610445Q'Q!\=)X6LQ:611]5G7* \B% M?[Y'KZ#_ YN$)3ERQ$VDKLL^,O'^G^%(F@7%SJ3+E+=3PF>A<]A[=3^M>%Z M_P"*-6\2W1FU*Z9U!RD*\1Q_1?Z]?>LN>>6ZN))YY'EFD8L[NI)J.O9H M8:%)=VF?!6_FB#ZGJD-LQ M /EPQF4CV)) !^F:TJ5J=/XF*,)2V/+:*]R3X+^'P@$E_J;-W*R1@?EL-9E] M\$EVNVGZR0W\$=Q#P?JP/]*Q6-HOJ5[*1Y!4MMMJRNBNC!E89# Y!%?(U>D_#3QZVDW$>BZI-G3Y M6Q#*Y_U#'MG^Z?T_.N#$X-6YZ?W&U.KTD>XT445YAT'FWQI_Y%:Q_P"OT?\ MH#UX=7N/QI_Y%:Q_Z_1_Z ]>'5[."_A'+6^(UO"[K'XMT5W8*JW\!9F. !YB M\UW7CCXI3WLDNF^'Y6AM0=KW:\/+_N_W1[]3[=_+Z*VE1C.:E+H0I-*R%))) M)))/))I*U=$\.:MXBN3#IEF\Q7[[]$3ZL>!7HNG_ 3D**VI:PJ-GYH[:+<, M>S,1_P"@T5*].GI)A&$I;'DM%>YGX+^'_+P+_4P^.IDCQGZ;*P=3^"EW%$7T MS58KAQD^5/&8^/9@3S]0*SCC*+>Y3I21Y55[2=9U#0[Y;S3KJ2"9>I4\,/1A MT(]C2:KI&H:)>M::C:R6\P[..&'J#T(]Q5*NC22[HSU3/HSP1XZM?%MJ8W58 M-2A7,L /##^\OM[=OU/75\H:7J=UH^I0:A92F.X@;'M;M M_$.AVVIV_"S+\R9Y1APR_@:\C%X?V3YH[,ZJ<^969IT445QFH4444 %%%% ' M,?$/_D0=7_ZY#_T(5\V5])_$/_D0=7_ZY#_T(5\V5ZV _AOU.:M\04445W&) M]!?"7_D0X/\ KO)_Z%7<5P_PE_Y$.#_KO)_Z%7<5X%?^++U.V'PH****R*"B MBB@ HHHH ^=/B?;_ &?X@:EA B2>7(N!URBY/YYKD*]#^,J@>,[<@#FQ0G_O MMZ\\KW\.[TH^AQ3^)A74_#B;R/'^DMG :1D_[Z1A_6N6K9\)2&/QCHK _P#+ M]"/P+@&JJJ\&O(4=T?4-8?BWQ%#X7\/SZC(%:7[D$9_CD/0?3J3[ UN5X'\6 M/$!U7Q1_9\3YMM/'EX'0R'[Q_#@?@:\7#4O:U+/8ZZDN6-SB+R\N-0O)KNZE M:6XFZE8XPJ6VM;B\N4M[6&2:>0X2.-2S,?8"GV-E<:E?0V5I M$9;B=PD:#N37T7X-\%V7A.P 54FU"1?W]SCD_P"ROHO\^I]L,1B(T5YEP@Y, M\UT?X-ZO>1K+J=W#8*>?+4>:_P"." /S-=(OP5T<+\^IWY;U&P#^5>FT5YGY5YWK_A76/#4P34K1D1CA)E^: M-_HWK['!]J^H:@O+.VU"TDM+R!)[>4;7C<9!%:4\;4B_>U0I48O8^3**['Q] MX)D\)ZBLMONDTRX8^2YY*'^XQ]?3U'T-<=7JPFIQYHG,TT[,*]>^$'BIFW^' M+N3. 9+0G\V3_P!F'X^U>0U:TV_FTO4[:_MSB:WD61?<@]/I45Z2J0<1PERN MY]85YK\:?^18L/\ K\'_ * U>A6%[%J.GVU[ >_&G_D6+#_K M\'_H#5X^&TK1.JI\+/#Z***]TXPHHJWI>F7>L:E!I]E$9+B9MJK_ #)] !R: M&TE=@5*W[#P1XFU)-]MHMUMQD-(OE@_0MC/X5[?X1\ Z7X7@CE,:7.I8R]TZ MY*G'1!_".3[GO765YU3'V=H(WC1[GSG_ ,*Q\8XS_8Y_\"8O_BJ]7^&&B:CH M'AFXM-3MC;SM>-($+*V5*(,\$CJ#7:T5RU<5.K'EDD:1IJ+NCQ#XT_\ (SV' M_7F/_0VKS2O2_C3_ ,C/8?\ 7F/_ $-J\TKU,+_!B<]3XF%%%%;D!6[HG@[7 M_$"B33M.E> G_7OA(^N#ACC.,=LUU?PS\!Q:X_\ ;.J1[[")\0PGI,XZD_[( M].Y]@0?<$18T5$4*BC"JHP /05PXC&>S?+#5FT*5U=GA(^#?B4KGS].!]/.; M/_H-8FL?#[Q+HD3S7&GM+;IRTMNPD 'J0.0/9'/*+B[,****T) M"E56=U1%+,QP !DDT*K.X15+,QP !DDU]!> O 5KX;L8;V\A635Y%W,[<^3D M?=7T.."?KVK&O7C1C=EP@Y,\LTSX8^*=3C$GV%;2-AD&Z?83_P !Y8?B*T9/ M@[XF1"RRZ?(0,[5F;)]N5%>\T5YSQU6^EC?V,3Y:UGPWK'A]U75-/EMPW"N< M,C'T##()XZ9K*KZSN[.VO[22UNX$F@E&UXW&017SKX\\)MX4UWR8MS6-P#); M.W8=U)]1_(@]Z[,-BE5?++1F52GRZHY:BBBNLR.R^&>OMHOB^WB=\6U\1;RC M/&3]P_@V/P)KZ(KY'1VC=70E64Y!'8U]5Z/?#4]%L;\8_P!(@24X[$J":\O' MPM)374Z*+TL7:***\\W"BBB@ KY%KZZKY%KTLN^U\OU.>OT"OH3X4?\ (@6G M_767_P!#-?/=?0GPH_Y$"T_ZZR_^AFM-F:9LX'11V4>P'%4**U/#VB7'B+7+;3+;AIF^9\9" M*.68_05[VD(^2./5LV?!'@>Z\77C.Q:#386Q-/CDG^XOJW\OR!]^TC1M/T*Q M6STZV2"%>NT'?%GPDFEZ@FMV2$6UXY$Z!>(Y>N?^!G@\2 MV_9S^1SU:?VD>;5[W\+?%K:[H[:;>2%K^R4 ,W62+H#[D=#^'K7@E;/A77)/ M#OB2SU%2=D;[95'\49X8?E^H%=6)I>UA;J9TYP' 'H*]!^,6OM=ZU!HD3GR;-1)* >#(PXS]%(Q_O&O,Z]C!4>2',]V< MM65W8*Z_P-X%N?%MV992T&F0MB68#EC_ '5]_?M6-X;T&X\2:];:9;DKYAS) M)C(C0?>;_/? KZ:T[3[72M/@L+*)8K>! B(H_4^I/4GN3FC%XCV:Y8[L*<.; M5C-+TFQT6Q2STZV2"!/X5')/J3U)]S5VBBO(;;=V=04444@&NBR(R.H9&&&5 MAD$>AKR#X@?#)+:&76- A(C7+SVB_P ([LGMZC\O2O8:*UI5I4I7B3**DK,^ M1:*]%\?_ ^O;+7C(OY+]UP!P.X_$=JY/_A$?$G_0 U/_ M ,!7_P *]N%:$XJ29R.+3L>Q?"OQ2VMZ&=.NGW7M@ N2>7B_A/U'0_AZUW]? M/W@G3O$OA[Q797K:'J:P,WE3YM7QY;<$GCMP?PKZ!KR,5",:EX[,Z:;;CJ>; M?&G_ )%:Q_Z_1_Z ]>'5[C\:?^16L?\ K]'_ * ]>'5Z&"_A&-;X@KJO W@V M;Q;JI5RT6GV^&N)1UYZ*ON?T'/H#RM?37@K04\.^%;.SV 3LOFW![F1N3^7 M^@%5BJSI0TW8J<.9ZFMIVG6>DV,=E86Z06\8PJ(/U/J?J?!? M6C%?WNBR-^[F3[1$">C# 8#W(P?^ UY76_X'O7L/&^CS( 2UTL1SZ/\ (?T8 MUZ->'/3:,(.TDSZ;HHHKP#M"BBB@ HHHH YCXA_\B#J__7(?^A"OFROI/XA_ M\B#J_P#UR'_H0KYLKUL!_#?J3_ -"KN*X? MX2_\B'!_UWD_]"KN*\"O_%EZG;#X4%%%%9%!1110 4444 >$_&8_\5E;>UBG M_H=UV7Q3N'F^(.H(S96%8HT]AY:DC\R:XVO?PZM2CZ'%/XF%:_A52WC#1 M0!_R_P '_HP5D5TOP^@%QX]TA",XF+_]\J6_I55':#?D*.Z/HO4KU--TN[OI M/N6\+RM]%!/]*^4[B>2ZN9;B9MTLKEW;U).2:^BOB5+_ +[%?)5%<5;!NK-R\7_ 'V*/M5O M_P ]XO\ OL5\E45G_9_][\"O;^1]:_:K?_GO%_WV*/M5O_SWB_[[%?)5%']G M_P![\ ]OY'T[XHTVS\1>'+S37FAWR(3"Q7%V\ MSIO>D>'T445ZQS!7L_P:T%(M.NM=E3][,Y@@)'1!]XCZGC_@->,5],^!;-;' MP-HT*G(:V6;\7^<_^A5QXZ;C3LNIK15Y7.AHHHKQSJ"BBB@#Q#XT_P#(SV'_ M %YC_P!#:O-*]+^-/_(SV'_7F/\ T-J\TKW<+_!B<=3XF%*JEW55ZL<"DJSI MW.IV@/\ SV3^8K=NRN0CZDT?38M'T>STZ$#9;Q+'D#&2!R?Q.3^-7:**^<;; M=V=X4444@*U_9QZCIUS93?ZNXB:)OHPQ_6OE!U*.R'JIP:^N*^3M1_Y"=W_U MV?\ ]"->EE[^)&%?H5J***](YSLOA?I::IXXM3*@:.U1KE@?5X5X^.;=6QU4?A"BBBN,U"N ^+^FK>>#?M@5?,LIT M?<1SM8["!^)4_A7?UR/Q._Y)WJOTB_\ 1J5K0;56-NY,_A9\YT445[YQ!7TA M\-ISR+@M^9Q_P!\UXS4J7-Q&H5)Y%4= KD"NVO3=2'*G8QA+E=SZUHKY,^VW7_/ MS-_W\-'VVZ_Y^9O^_AKA_L]_S?@;>W\CZSHKY,^VW7_/S-_W\-'VVZ_Y^9O^ M_AH_L]_S?@'M_(^LZ*^3/MMU_P _,W_?PT?;;K_GYF_[^&C^SW_-^ >W\CZS MK)\3:.FO^'+[364%I8CY9/9QRI_,"OF+[;=?\_,W_?PT?;;K_GYF_P"_AIK M23NI"=9/H0LI1BK A@<$'M24I))R3DFDKTC ^COAOJAU7P-8,[;I;<&W?G^Y MP/\ QW;74R2)#$\LC!412S$]@.M>6_!*\+Z=JUD>D4L\OY?OW$S2'VRZUF1/WMT_E1$]HUZX^K?\ H(KT^L3P?9BP\':1 M;@8(M49A_M,-Q_4FMNO KSX_&G_D5K'_ *_1_P"@/7AU>S@OX1RUOB-#0;=; MOQ%IELXRLUW%&0>X+@5]55\N>%/^1QT3_L(0?^C%KZCKFS#XHET-F%%%%>>; MA1110 5QGQ4@CF^'U^[KEH7B=#Z'S%7^3&NSKD?B?_R3O5?^V7_HU*UH?Q8^ MJ)G\+/G.I()GM[B.>,XDC<.I]"#D5'17OG$?75%%%?-G>%%%% !1110!S'Q# M_P"1!U?_ *Y#_P!"%?-E?2?Q#_Y$'5_^N0_]"%?-E>M@/X;]3FK?$%%%%=QB M?07PE_Y$.#_KO)_Z%7<5P_PE_P"1#@_Z[R?^A5W%>!7_ (LO4[8?"@HHHK(H M**** "D=UC1G=@J*,LS' ]:6N)^*'B!=&\)RVL;XNM0!@0>B?QG\CC_ ($* MNG!SDHKJ)NRN>$ZSJ']JZY?:AA@+FX>4*QR5!8D#\!Q5&BBOH4K*R.$*] ^# M]B;GQFUR5RMK;.X;T9L*/T+5Y_7MOP8THV^A7NINN&NIA&A/=4[_ )L?RKGQ M<^6D_,NFKR-CXK[O^$ N\=/-BS]-X_\ K5\]5]'_ !)M7N_ &J)']Y$27\%= M6/Z U\X5E@'^[?J76^(****[3$**U+/PWK>H6JW-GI-Y<0/G;)%"S*<'!Y'O M4_\ PAWB7_H ZC_X#M_A4\\5U'9F)16W_P (=XE_Z .H_P#@.W^%'_"'>)?^ M@#J/_@.W^%'M(=PY68E%;?\ PAWB7_H ZC_X#M_A1_PAWB7_ * .H_\ @.W^ M%'M(=PY68E%;?_"'>)?^@#J/_@.W^%'_ AWB7_H ZC_ . [?X4>TAW#E9B4 M5M_\(=XE_P"@#J/_ (#M_A1_PAWB7_H ZC_X#M_A1[2'<.5G9_!20CQ!J4?9 MK4-U]''^-=%\:?\ D6+#_K\'_H#51^$6@:GI6HZG/J-ABBBO+.@**** /$/C3 M_P C/8?]>8_]#:O-*]+^-/\ R,]A_P!>8_\ 0VKS2O=PO\&)QU/B859T[_D* M6G_79/\ T(56JSIW_(4M/^NR?^A"MI;,E;GUC1117SAW!1110 5\G:C_ ,A. M[_Z[/_Z$:^L:^3M1_P"0G=_]=G_]"->CE^\C"OLBM1117IG.>E_!7_D9K_\ MZ\S_ .AK7M]>(?!7_D9K_P#Z\S_Z&M>WUXV-_C,ZJ7PA1117(:A7(_$[_DG> MJ_2+_P!&I775R/Q._P"2=ZK](O\ T:E:4?XD?5$R^%GSG1117T!Q!7T-\*O^ M2?V/_727_P!#-?/-?0WPJ_Y)_8_]=)?_ $,UQ8_^$O4VH_$=I1117D'2%%%% M !7R+7UU7R+7I9=]KY?J<]?H%?0GPH_Y$"T_ZZR_^AFOGNOH3X4?\B!:?]=9 M?_0S6N/_ (2]2:/Q&UXR_P"1+UK_ *\I?_037S#7U5KUJ;[P[J5HOWI[66,? M4J0*^5:C+W[LD57W0445]$^ ;?3=3\#Z7/)8VDDBQ>4[&%23?!*7&IZM%_>AC;\F(_K7 M?_$//_" ZOC.?*'3_>6N@@L;2U8M;VL$+,,$QQA2?RK+\86IO/!VL0*,L;20 MJ!W(&1_*N.553K*=NQJHVA8^8****]PXSZNTG;_8UCM^[]GCQ]-HJY6'X-OA MJ/@W2+D')-LB,?\ :4;3^H-;E?.R5I-'\O[6W4 M=Y9E7^9KCM<^+/A_3%9+%GU*X' 6+Y4!]W(_D#5PI3G\*$Y);G8ZIJEGHVG3 M7]_,L5O$,LQ[^@'J3Z5\V^+/$MQXIUV6_F!2(?)!%G_5H.@^O<^])XD\5ZKX MINQ/J,PV)_JX(P1'']!Z^YR:Q*];#8;V7O2W.:I4YM$%%%%=9D2VMM->7<-K M;H7FF<1HH[L3@"OJ70]*CT30[/38L%;>((2/XF[G\3D_C7D_PA\*M>T445ZIS'K7P9\0(C76@3N TC?:+;/QNX;NVD:*>%P\;KU4CI7T+X+\>6/BJU2&1DM]41?WMN3@/\ M[2>H]NH_4^7C:#4O:1V.FE/3E9U]%%%>>;!115#6-9L-!T][W4;A885Z9ZL? M11W--)MV0%BYO;2SV_:KJ&#?G;YL@7..N,U7_MO2?^@I9?\ @0G^-?.?B_Q3 M<^+-::]F!C@0;+>'/^K3^I/4G^@%8%>A'+[QO)ZF#K:Z(^J_[;TG_H*67_@0 MG^-']MZ3_P!!2R_\"$_QKY4I\,,EQ/'!"A>61@B*.I). *K^SU_,+V[['UG# M/#-@P/XBO.?C3_P BQ8?]?@_] :NX\/Z4FAZ!8Z:F#]GA"L0. M&;JQ_$DG\:X?XT_\BQ8?]?@_] :N3#V]LK=S6?P,\/HHHKW#C"OJ/PI_R)^B M?]>$'_HM:^7*^H_"G_(GZ)_UX0?^BUKS\P^%&]#=FO1117EG0%%%% 'B'QI_ MY&>P_P"O,?\ H;5YI7I?QI_Y&>P_Z\Q_Z&U>:5[N%_@Q..I\3"K.G?\ (4M/ M^NR?^A"JU6=._P"0I:?]=D_]"%;2V9*W/K&BBBOG#N"BBB@ KY.U'_D)W?\ MUV?_ -"-?6-?)VH_\A.[_P"NS_\ H1KTOT"OH3X4?\ (@6G_767_P!#-?/=?0GPH_Y$ M"T_ZZR_^AFM5_\ '2*^I*\> M^,WA\K-:Z_"ORL/L]QCL1RI_+(_ 5RX&IRU.5]36M&\;GDU>O_!?6U\J^T.5 M@&#?:80>XX##]%/XFO(*OZ-JUSH>L6VI6AQ- ^X ]&'0J?8C(_&O2KT_:4W$ MYX2Y97/JNBL[0]:L_$&D0:E9/F*4*ET_21H=K+_I=V,S;3S'%_BW3Z U=.FZDE%"E)15V>DT5\D>;)_S MT;\Z?%]HGFCAB,CR2,%10>23P!7=_9[_ )OP,?;^1]:4UT66-HW4,C JP/<& ML[P]I0T/P_8Z:#DP1 .W]YSRQ_$DUIUY[LGH;GRGK&G/I.M7NGR?>MYFCSZ@ M'@_B.:HUZA\9/#YM]4M]=A0^5= 13$=I%'RG\5'_ ([7E]>_1J>T@I'%./*[ M'M'P9UU9M-N]$E?]Y;MY\(/=&^\!]&Y_X%7J5?+&@:U<>'M;M=3MN7A;+)G M=?XE/U'Y=:^FM(U6TUO2[?4;*3?!,NX9ZJ>X/H0>#7F8VBXSYULSHI2NK%VB MBBN(U"BBB@ HHI&8*I9B H&22>!0 M%?/'Q%\7'Q'X@*6DI_L^TS'"5/$A_B M?\>WL!7'^;)_ST;\Z[X8"4HIMV,7629];T5\W> =(EU_Q?9P,7:WA;SY^>-B MG.#]3@?C7TC7/7H^RERWN7"7,KGFWQI_Y%:Q_P"OT?\ H#UX=7N/QI_Y%:Q_ MZ_1_Z ]>'5Z6"_A&%;XC7\*?\CCHG_80@_\ 1BU]1U\N>%/^1QT3_L(0?^C% MKZCKFS#XD70V84445YYN%%%% !7(_$__ ))WJO\ VR_]&I775R/Q/_Y)WJO_ M &R_]&I6M'^+'U1,OA9\YT445[YQ'UU1117S9WA1110 4444 &N)\<(OH/]H]A_A5CPCX&U/Q9 M)Q M2IKECO\ D:TZ;EJ]BS8V-MIEA#96<2Q6\"!$1>P_J??O5BBBO';N=05C^)_# M\'B;0;C39SM+C=%)C_5R#HW]#[$UL44XMQ=T#5SY.U#3[K2M0GL;R(Q7$#E' M0]C_ %!Z@]Q5:OH7X@>!8_%5F+JTVQZI N(V/ E7KL/]#7@%U:SV5U);74+P MSQ-M>-Q@J:]RA756/F<F:A\:-7G1EL-/M;3/\3L96'TZ#]*X'5-9U'6[K[3J5Y+NH_P#1;0[8 ?XY?7Z*/U(]*YKP M9X-O/%NI!5#16$3#[1<8Z#^ZOJQ_3K7T586%KI=A#964*PV\*[41>P_J??O7 M#C,0HQY([LVI0N[LLUYK\:?^18L/^OP?^@-7I5>:_&G_ )%BP_Z_!_Z U<&& M_BQ-JGPL\/HHHKW3C"OJ/PI_R)^B?]>$'_HM:^7*^H_"G_(GZ)_UX0?^BUKS M\P^%&]#=FO1117EG0%%%% 'B'QI_Y&>P_P"O,?\ H;5YI7I?QI_Y&>P_Z\Q_ MZ&U>:5[N%_@Q..I\3"K.G?\ (4M/^NR?^A"JU6=._P"0I:?]=D_]"%;2V9*W M/K&BBBOG#N"BBB@ KY.U'_D)W?\ UV?_ -"-?6-?)VH_\A.[_P"NS_\ H1KT MOT"OH3X M4?\ (@6G_767_P!#-?/=?0GPH_Y$"T_ZZR_^AFMK:9;:SI M5SIUVNZ"X0HV.H]"/<'!'TJY17DIM.Z.H^6-?T.[\.ZS/IMXI#QGY7QQ(O9A M['_ZW:LROI'QOX,M_%VF!05AU" $V\Y''^ZW^R?TZ^H/SQJ.FWFDW\ME?0/! M<1'#(W\QZCW%>WA\0JL?,XYP<6;/A'QC?^$K\RV_[ZUD(\^V8X#^X]&]Z]^\ M/>*-*\36GGZ=0/Q)']1_4<5\O5+;75Q9W"7%K/)!,ARLD;%67Z$5-? M"QJZK1CA4<=#ZUHKP32?B[XBL L=X+?4(P1DRIMDQZ!EP/Q(-="GQOC.?,T! ME]-MWG_V05Y\L%63T5S=58GK5%>0R_&]BKB'0 &_A9[O(_$!/ZUR>L_$WQ-K M$9B-VEG"PPR6:E,_\")+?KBG'!56]=!.K%'JOC3XB6'AF&2UM6CN]4(P(@OTZUX#>WMSJ-[->7DS37$S%Y';J3_GM4!))R3DFBO2H8>-):;F$Y MN05Z5\)/"S:AJQUVY3_1;-L0Y_CEQU_X"#GZD5RWA'PE?>+-4$$ ,=K&0;BX M(XC7V]6/8?TKZ/T[3[72=.@L+*(16\"[44?S/J3U)]:PQF(48\D=V72A=W9: MHHHKR3I,[7=&MM?T6YTRZ'[N=X.#7S)J^DW>AZK<:=>IMG@;:<= M&'8CV(YKZLKC_'G@>#Q98"6';%J<"D0RGHXZ[&]O0]C]377A,1[.7++9F52' M,KH^=:Z?P;XUO?"-Z2@,]C*A]3:%XBTSQ'9"ZTVY650!OC/#QGT9>W\JU*^3+2] MNM/N5N;.XEMYU^[)$Y5A^(KO-+^,/B"S")?16M^@.69E\N0CTRO'_CM>94P$ MD[P=SHC674]WHKR+_A>'_4N_^3O_ -KJEJ'QJU.50-/TJUMN,$S2-*?J,;0/ MQS62P=9]"O:P/9;FY@L[=[BYFCAAC&7DD8*JCW)KQ7X@?$HZS')I.BLZ6!XF MN.C3C^Z!U"_J?8=>)UGQ)K&ORA]4OYKC!RJ$X1?HHP!^595=M#!J#YIZLRG5 M;T0445ZM\,_A])/+#X@UB+; I#VENPYD/9V'9?0=^O3&>FK5C3CS2,XQX_&G_D5K'_K]'_H#UX=7K8+^$>;A1110 5R/Q/\ M^2=ZK_VR_P#1J5UUJ_]LO_ $:E:T?XL?5$R^%GSG1117OG$?75 M%%%?-G>%%%% !1110!S'Q#_Y$'5_^N0_]"%?-E?6&I:=:ZMI\UA>QF2VF&UT M#%HY[5S'_"K?"'_0+;_P)E_^*KNPN)A2BU(QJ4W)W1\[45]$_P#"K?"' M_0+;_P "9?\ XJC_ (5;X0_Z!;?^!,O_ ,573]?I=G_7S(]C(^=J*^B?^%6^ M$/\ H%M_X$R__%4?\*M\(?\ 0+;_ ,"9?_BJ/K]+L_Z^8>QD?.U%?1/_ JW MPA_T"V_\"9?_ (JC_A5OA#_H%M_X$R__ !5'U^EV?]?,/8R/G:BOHV'X9^$( M7#C2 Q']^>1A^1;%;ECH&CZ:V^QTNSMWZ;XH%5OSQFIEF$.B8*@^K/G?2/!' MB+6RIM-,F6(_\MIAY:8]F M45RU,94GHM#2-**&111PQ)%$BQQHH5448"@= !V%/HHKD-0HHHH **** "N: M\6^"=,\6VX-P#!>1KMBND&64>A'\0]ORQ72T549.+O$32:LSYH\2>"-;\,R, MUW;&6U!^6ZA!9#]?[I^ML?#;PQK!9VL?LDS?\ +2T/ MEG_OG[OZ5Z-+']*B,)4?Y3YRHKV"[^",9>1K/7&5/X$FM]Q_%@P_E6._P7\0 M!R([_3&7L6DD!_+8:Z5BJ+^T9NG+L>;T5ZG:?!*_K-%%<#=]6; M!7FOQI_Y%BP_Z_!_Z U>E5EZYX>TSQ':QVVJ6YFBC?S%42,N&P1GY2.Q-:49 MJ$U)]"9*ZL?+-%?1/_"K?"'_ $"V_P# F7_XJC_A5OA#_H%M_P"!,O\ \57I M_7Z79_U\S#V,CYVKZC\*?\B?HG_7A!_Z+6L7_A5OA#_H%M_X$R__ !5=7:6L M-C906ENNR""-8HUR3A5& ,GV%8_]#:O-*^G=<\':'XCNH[G5+,S2QIY:L)77"Y)Q\I'E1QE.%-1:>AA.E)RN?.U6=._Y"EI_P!=D_\ 0A7T!_PJWPA_ MT"V_\"9?_BJ=%\,?"4,J2IIC!T8,I^T2<$?\"K1X^FU:S_KYDJC(Z^BBBO). MD**** "OD[4?^0G=_P#79_\ T(U]8UR$GPQ\)32O*^F,7=BS'[1)R3_P*NO" MUXTF^;J9U(.6Q\Z45]$_\*M\(?\ 0+;_ ,"9?_BJ/^%6^$/^@6W_ ($R_P#Q M5=GU^EV?]?,R]C(X'X*_\C-?_P#7F?\ T-:]OK"T/P=H?ARZDN=+LS#+(GEL MQE=LKD'^(GN!6[7GXBJJE3F1M"+BK,****P+"N1^)W_).]5^D7_HU*ZZJ>JZ M79ZUILVGW\1EM9L;T#%I]?I=G_7S.?V,CYVKZ&^%7_)/['_KI M+_Z&:?\ \*M\(?\ 0+;_ ,"9?_BJZ/2=(LM#TZ.PT^(Q6T9)5"Q;&3D\DD]3 M7-B<5"K#ECD:/8Z%IR6&G0F*V0DJAN3KZZKF=9^'_AO7"[W&G)#.V?WUL?+;)[\<$_4&O1I8_I M41C*CV/FNBO8[SX)6SREK'6YHH\<)/ )#G_>!7^58LOP6UT/B'4--=/5V=3^ M04_SKJ6+HOJ9.G)=#S:BO3[7X*:H[?Z9JUG".YA1I/Y[:W+#X*Z9$ASN/Y$4I8NBNHU2DSQ559V"J"S$X Y)KT'PK\*M4U=TN=6#Z?9 M<':P_>R#V'\/U/Y&O7]'\)Z%H'S:;IL,4G_/4@O)_P!]-DX]JV:Y*N/;5H*Q MI&BEN4]+TJRT:PCLM/MT@MX^BKW/J3W/N:N445P-MN[-PHHHI %%%% '-^*_ M!6F>++5_2N2N_@BI>1K/7"%S\DD5N9!^9*UH\517VB?9R['E-7--TJ_UB MZ%MIUI+@'N:]MTSX/^';,J]X]U?/C!61]B9]0%P?U-=Q8Z?9: M9;B"QM(;:$<[(4"C]*YZF/BO@5RXT7U/._!WPHM]->._U[R[JZ7YDMAS&A_V MO[Q_3ZUZ;117G5*LJCO)F\8J*L@HHHK,H\V^-/\ R*UC_P!?H_\ 0'KPZOJ? M7/#^F>([2.UU2W,T,@8KG!##D<]0*NG)1FI/HQ25U8^4:*^B?\ A5OA M#_H%M_X$R_\ Q5'_ JWPA_T"V_\"9?_ (JO4^OTNS_KYG/[&1V-%%%>0=(4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% < !1110 4444 %%%% !1110 4444 %%%% '__V0$! end EX-101.SCH 4 dmtk-20220301.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 dmtk-20220301_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 6 dmtk-20220301_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information
Mar. 01, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 01, 2022
Entity Registrant Name DERMTECH, INC.
Entity Central Index Key 0001651944
Entity Emerging Growth Company false
Entity File Number 001-38118
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 84-2870849
Entity Address, Address Line One 11099 N. Torrey Pines Road
Entity Address, Address Line Two Suite 100
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code 858
Local Phone Number 450-4222
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock,par value $0.0001 per share
Trading Symbol DMTK
Security Exchange Name NASDAQ
XML 8 dmtk-8k_20220301_htm.xml IDEA: XBRL DOCUMENT 0001651944 2022-03-01 2022-03-01 false 0001651944 8-K 2022-03-01 DERMTECH, INC. DE 001-38118 84-2870849 11099 N. Torrey Pines Road Suite 100 La Jolla CA 92037 858 450-4222 false false false false Common Stock,par value $0.0001 per share DMTK NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 122 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports dmtk-8k_20220301.htm dmtk-20220301.xsd dmtk-20220301_lab.xml dmtk-20220301_pre.xml dmtk-ex991_6.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dmtk-8k_20220301.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "dmtk-8k_20220301.htm" ] }, "labelLink": { "local": [ "dmtk-20220301_lab.xml" ] }, "presentationLink": { "local": [ "dmtk-20220301_pre.xml" ] }, "schema": { "local": [ "dmtk-20220301.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "dmtk", "nsuri": "http://dermtech.com/20220301", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "dmtk-8k_20220301.htm", "contextRef": "C_0001651944_20220301_20220301", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "dmtk-8k_20220301.htm", "contextRef": "C_0001651944_20220301_20220301", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20220301/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-22-008032-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-008032-xbrl.zip M4$L#!!0 ( +: 852+W"QONP0 %H6 1 9&UT:RTR,#(R,#,P,2YX M^__S\[$5SRF7",J5-28\DL8]#88]OO>Y:!_=A%>_1D$PR"H*?@O/P.J_8;HW N\GG<97M48/V/R M#2\ C4QJ ' 6P.55+R*#^<7Y!8G"LW!P44>:I&M!%TN%WI"W M%J(^+^? &*S1/>68$XH9>BA/^@Z-.?'0'6-H:L0DFH($\0215VA=R6@H<\_I M:' YC(#>.(7G5C/!/ G$6R1/OB;XVF+O^YE3L.H0J74*LN*?8SGS$K'P2XH5 M<(.>V^^50E*EHMF H5B!BE6H0P8J4H,%6)%ELP5#V;9 R0$LE&PQ&F*DMGD- MCC (SOV<6$/=B+<)*<_BL$EI&&BL"KBD,P:N80-A4U2ZH2F3RO\+C--&]QM" M@T6.*9'-1[:DO4-ODL&44?W<@A+0=T"$RFQDVU;B#39-V0;'>/4FF2L M-K B$+$"LK1-QE1HT \T)U9*T%FFX#X1\0CF.&,Z33+^/<.,SBE$NONV7)[HRR)_!?"*-.E$XQ-KG6&438"8__\ MD.7FSG&:3;EO]'BC. '$SSK-Z<@.5GOYX9J/HY":>T57"/4BK[Y:@-AN$AU1 M;&Y-LW3SY4GVZ_=MQ_QHZ%GV6YY4%XT=KZ,;JIO7KDX/0NW&[E:73 @?"R(2 M!OI^).K#*F688Y78? P&ID_T+D[M$X,M72YLE-WK[Y=@M$HY+/0$&G4"5E?P M"D#42T"TZF@'AI!\>7JFU,>7CL;+H<\L3C>\&15;FMT;#GU@2MK1=C.X'8)P M<+)\/1 FF+(EE%SH%P&RK:LMH/U70M?L*)\G=M4B/S;/FJZNJ,_SN3N*G3;. M:'H4O"J@UOE2ROPZ2*TSIO'A6H.$.4^4Q6'WRMTTI7R>%%MZTTR30W.V1ZT, M43V#/T*L[PH%$_M(,:1_I^/C,WS>3;<%V[V;*D EI CFE%,+/S _Y-;_7E*: M0L;6M;\KL:LLDQ#]PV_M.A4@M1+KF9ITP7),DF!&,M9!<(/LL%RQ6T9B)T"E MGZ8P1_;U."QN]^-O3#\520I"49TFM2>J5; 4,+]QS(/0+&9I^-6LNP9 MV Z>#;H6 3;9P"ME%55&>&+(-DKR'<*L4FU2]\:1NFY8]9#YWX^K4Z'M<7>S MI_G4GVM-II:?P*N%)O,[QE352_G_'HP]81RM6AFKYVY=JYZ+K7>?=RO?9W>VRQ4^_%^59^5=S^ %!+ M P04 " "V@&%4/,=T&#,' !63 %0 &1M=&LM,C R,C S,#%?;&%B M+GAM;,U<:V_B.!3]OM+^!R_S948[(1 Z;4'3CKJT7:'MM%5A=D>[6HU"8J@U MQF;MT,*_7SN/EH 3\C"#4:6&8)]S?>ZYL1T>'S\M9Q@\0<81)6>-=K/5 )!X MU$=D>M98<,OE'D(-P .7^"ZF!)XU5I W/IW__-/'7RP+7%X/;L&%%Z G>(FX MARE?,/AV^/D=^/K;PPVX0>3[V.407%)O,8,D !9X#()YS[:?GY^;_@013O$B M$.R\Z=&9#2PK@>XSZ,H7P*4;0! ^>L!I.8[5$G^GHY;3.^KV.IWF2;=S=.R< M_MIJ]5JM-8 _HV&!M4];Z[4P@&EVL-.\[DI-5UQJ== M"(]:\.2T[7O=R?&'8\]WCISN\7JD=+YB:/H8@+?>NS!$,5Y"(,9P!:X1<8F' M7 R&R4C?@P'QFN "8_ @NW'P #ED3]!OQJA8Z-;#B7@B1X2'3\\::^HMQPPW M*9O:3JO5L9/6C;CYYVNW;XZDM3CE0-!6S;_OKY9N@]PIEKB50) M%WB2@*,>#T_>4"_,48&X0&8+^1^0Z@!0*0'HQ@^P F0 M_[\\##(YN[9L81,X%<;Q;]PQQ"+F$.*1P8FZ'V8LU4W&T95QM(]E'&]4:,%J M+NJ!H]D<"U7LVJ'>PD!OM)N N@.^APQ1_XIH%ED-NY_@AX'+-*N>!:Q[ "-Q M?8-Z0]^&U!XT#5RL.>@M2(U!5_!&L!UG72-,7#X.:<24/'7=>42%):CM+A&_ MA!-W@8/M,+GH',:XA2"FJ;8-<<#E&0G'+7G*:K7C2^\;!7!VY&$LSFABB.Y>(+$^C(L M"O8-CS?%:N$>6#A=<]/&)WEJAG3TITJV;J]T:=B 7PQYH+*"XIZ8J-3-2^D M0/1X(!+]/$0&_R38_QX^[6J5::80VM.<;$%&8HA%LYSN4RW)ZQCZZ_QE8R7A M#Y]EI<@T2PA3!,6EM*QOQ0O!XDNF:^Q.BWIQHU,U[5(@^MWX @\D_N'MJ!:: M9FIAC*BXG)[ZKHXO>R]YUZ7L97*C<[WR3H'M\<(9\0!!%-YI.KQI\U-!=ZID MG.R;E]?"BNM:]S_ *9)K"Q+*20KC\N+J,NN >)3-*0O?YQL&8KW6IPLQQTQ=DJEBI=Q31REP-?K+O0 M!$5OG%>9!C)!ZB0C W1OI2/X0)K0L.EB5ZIH8?6,30NNFQ%=97'A^R)^'O^[ M002VRY6$$J".[@K O95"3/(^.9"?FH+@CA@S=>2EAQ92S78/6 MKW#[-[WDDML%R6:8X15)4=E]4RT#$Z"V>BC]W2[I-3L]W'' MLS T2+Z!N7_COVR4$TK#W)^5*%4)*,4S-2GJ8HC2<5"[M3(.-%Q-;WK6WI(,?)0@,CTLUB$,^3BHGY6]:RFZS:2 M?B>_TX+*\-3(0L8&0[O#F+I >6DPT,U.!7[( ^N6SH-W^ \X7D-4O @6. M%OVW<'] 042<9M=%=M[4U9&AH\DYRJJ44NG1L-2!WD*LKU9M9SQ" 2Y\[V.[ M7\79=P-'?P&$L(!.0-MY.WX'$L+#>SY3>IHGC4DR)TN<5W 0HN_3L"/FRA_" M&:YF8UIX6;[1J9J&*9 ]^#2"!Q'^X>VI%IIF:F&,J+B> SP4G#6!%E?/[T\T\W[TP3W=ZW'U$31W1.;JG" M3*B9)._[#Q_0E]]Z'=2A_'GH*X)N!9Z%A$?(1),HFM9M>[%86,&(9#OQ=#QRO7JW5*Q7KJE:I7GK7'QVG M[C@[!OY:AX5V/G5T83F6:UUYUSN"71\_^V."VK<[@A5O=.74O.%UC9"J0ZZN MW0#71I<7ESCPJE[MIF*XD'4\B]!Y_B"%"O)P3QL@*W5/NEI-H1Y11,Y)8&VL,N"MSA+RX!YQ%7]M&#OL+8>264*.;<]Q*G8B M;6S$EP?RBTHL[=9J-3N^NA55-$L0S+KVEX=.'T](Z)MPJR +L':@:%W%/W8$ MCN_1$;A0KH3^9B9BIO[)=#VSXEI+%1C !D)K/J1@I$=&2!__[+6W/@,BPXC@ M29Q FGVG L"UE#T@X91!^G36T<9F)I*,&D801L]F(JP]_9(E&ZVFD/&*PA6( MVWXSF,A?"B["U1I5\C DQR8/[GA$HU6;CX0,8T9?0]L#0U]/,90?RE1"]O$H MEM;![RF0941X0(+$C [@_,'&:!(\3."]X+4S!=[BK%$$6V,Q!]=4>W3_K>I3 M/4 YE-"ZCDZ##,VSP_L;$@UJDN9CQNFZ M_ZAC$>8HGQVD;HRL.X$!T^,L'!Y_HP_US@ZM!<]I$\96+1$<_7SOZYP=TKHA M-(, .I'J"AAGL'_H]!2 W[)0+-P^-$[R)+M2S.EZ='0ZX ,;Q4+6=_-)#L2" MOPGMKGJQ0#<'&)00[TU0]PW\,+#N]X)U"P,[\)?M %H('6VJWVGUZ14C!8&& MZ9*04R%C7_'#TA(S'LG5Z27B%5,%!7!/V8F-X%"O(&AW(9%CZ-B_2[&()M 8 MISY?G88RQT1!@%N0>-)G;1@"+?\@)T(]4"X(9(^,J0)//#IEZI&M>W:(R52L M"T,T ;.Q0*^P'(LQ1_GL()O@)-".[ID_/A;<"Z7"F!L CE,)6^N&Y?:1_4[GI 4^(]D[[$B3DXW5L,.%S8V4C84U^"/1-/*-NN(XRD M"#.Q;+R)+/*$A&E/PW =QW4LQS'0%')0SSL;!K3WF0(P8JIAZXD'A 'S(TF" MSCKN7)@Q1IBN*!)+_I_I>)'?*1^5E+LF9 MRUA;;KQ2%^2,U4A?D[+<$*3DEK<;[[WA2.DI:@ _?Q&TI MJ92T[N:\/$UY*6G5S7KMG9)2TEK[K2T+*3DEK;6O;T))*2II_3W<4K2EI%K2 M^OMB]U?*1UGK;N9.O926'U!Y;^P#5F"6]JSW\*ZOZ']Z7^NG_P!02P,$% M @ MH!A5".Q>3^/$0 +IT !0 !D;71K+3AK7S(P,C(P,S Q+FAT;>T] M:U/C2)*?]R+V/]1Y=C8@#LN2;,!V QN,@5Y?-X\ S^W$?9DH2V5<@RRIJTJ M]]=O9DDRDBV##>U'>TQT1%NJ5V96OBHKJW3TC^>!1\@C$Y('_G'),LP28;X3 MN-R_/RY%JE>NE_YQ\M?_.OKOGIX,M\=]&7B1@G&DX02#"BF7TXY;@E$L M(&=4,:+_FL0V;;MLPK]ZQ[2;M4:S6C4.&]7:@5W_']-LFF:F@_^+$2"9OR;9 M-TS#,@[M>J;B#74>Z#TC[;-,Q:K=.S0;=K?>8*QFLL.ZY3J-WL'^@>/:-;MQ MD(4T"(>"W_<5V7%V-8B K^\SSV-#N0NQ70/2.,8Y-3SR"TVD^26 M228>F6LDO?85S #,@B^;SUWA\>-2AFKXQ@C$?<4VS6H%**A@ %;*U'=?&F0K M'U3BPK2J.U /HXHN$P/%G+Z>!L3!K)I66C.2934,F1S5[E'9U=VF)=C$*IM6 MN9IM=$]I6-@&"PJ:2!6*/.B2.<9]\%C!$MU@5%6H:3"-BHI&$*JP05%5[DR! MA3LY4'S*'5E<51?E*K-GIU]<%TMR55TEQE#,33\45[ 8VY@(>J8EX\5C0($> MXELMK>I$0H!P#XOKIZ4YN)P@\I68UB(NS./L1P.[B"5M$[!6S)>\Z[$R5F-" M"[TLVZAU$I8&/?*0H\%357=@-1J-BBX=\9P24V6E48'2M.)$EWFIPN(NE2.I MXC*HV=;A:W(8UQC!+'D1Q%#5JOQV^?7.Z;,!+8\++W^>-H*%DH[Z%-7IB/% MRT2#-[@#*I4U8;DS:O=VHWP#_JR*&[S 5%&"^K(7B(&>0 1Y'S6U?9#II Q< MDNLHY9JW^JF_R.5T1D"M6=+JDU$7_Q\P1;6]*;-O$7\\+K4"'[A-E3N 8XDX M\=-Q20$35G1K4L%VBBN/P0]4D.7ZP^^I.C2@#A17TO*C2CH2FH&KSV )?#"; MB@GRB(;&-@Y3@]0-W.')DVW?9\Q4+AB1:/321J8]+D@]"#X5-O^L+A$C/ M\6B"GZ6;%E/AB !G:F8E,8>>FE7]G!Q5\OB\T&$,\9@6,HC$"RFT[]!,Z*^G M[2WZZW9I0Z;G,WF7ON0NONYQX'$-%"N4YU;[2WXRQQNG(U4*ADI&"F'> W=L M>-"70J%'>!*[@E4P?&DG+V7Y-B 14UJD)7E@L@.G[Q(B9LF?H77,F*GP'E5 MSN%_^!6FXMX-!!26NX%2P: )KB!WB6D<[H>*_*0ER?P44A<][+2.&:I/ RKN MN5_P1@6A?D28P(H@69OFSY]Z &59\G^SY@$4ED[^_I-U8'XZJH0G65AT(^KQ M>[_I0$,FWC?.$T/GM=D-/#(.6]^+.1VI?:\2XUB,5G,*()*E8.OGUJMTY/R-WG=/.^1W9(,3NSEN_WK8[ M;<#J].J,G/_6^N?IU>=STKJ^O&S?W;6OKY:,K;U(;/]%91]8707^'CDS6@8L MFO9K#7(D0^JGZ&5@,5-8$EA'_:3\C>U.YJ4/8E@DEM9,,CF3!+Y)P#Q"'Z+I MG+*.\!\4JIAU$8F+Z]M+,MWU,+.N1QI?R#AV,WH<]?*7<5=CRX8_&!LN5%>! M7KX]O^J0V_.;Z]O.)FGAFTC("%X1%9 [YN!R*YX]JTH"0:S]'7=WD_ ->D3U M&:(:":XX='S^[/2I?\\P@$F@V&I4:[-CO/Z\JT.G@-@!M^RX=#@$X MYI=.+F$!UB?6G@ZHCJOHK:OP@^EHN[9(/I_.M=7) ,4MN^<2^U574#*?MW!V M?GO9.6_]1X0R]&[;\ES@J-^3D@7 MX]BDD0I2$CF!Y]%0LF;ZXQ-YXJ[J ^L VCI4JG3 0KGD45,=NN&NBS&RI->4 MF![K*4V[](7>N:%_/&JUE@P:YF%^9::2Q]'H^:G#%R^3M[^R MR3NJ*'>,C#%*"R&CGN$%T_$-[!;))/;"F61U4V>M&K?-F[A*HL'&]1B,L2SI M>X>5GQ'S51C^Z;[4X:0OU?:=0,#B0>_5W2EPXUOQ_F\K<-^_'L!M0HSF*Q:* MX!''Q 7!&?/H$ZP-)L(U&Z>!9YO@99FRK21]=TDZF)2D"^XQJ-EE8MX=4ZM< MK5M6?2L66['XP<6B/BD6'?K<3C:-'6UDWB,C]5K9KA^:]5KC-2'Y$WH2"]V_ MV='^ $:2 ]5G@OP1"2Y=KN/,\Z[[K1\)\:!'>-8OVMT\53P3_;::>+WY=*<5 M# 9_-D:O V"UPPBHZ M"GZ29M(M:S-V17YO8]+O/75=P:1,_OO*?6;-Y_-:EMEHD"N#= (AV)#<0!<2 MT*#NN ^\-WW3US)G@#[*[B(-;:)EFD3.^(;MGTREJ3:5H"WY>BT[PY,]' MSZ^4_"_N[\PSK_94*+33?BUN1/#(]4!IG4YNB4Z%H6!K-H'A)I"*>O_/ MP[FCB"<-^/]PM?NRBS44"8EP3_9&P SQD'KD_)DY$1[!(]<]4*TP'/5= @0D M2,$YDGC67XN^[-[__:>Z;1U^DD0QCX5]:$-\[>3MX?++B]"3(%0P"@SD,K(S MG1-SIQA0#$^AU?R\5]^?",+MOL+_^]E1OP8.]6X0B?<$.&K[9KEF3Z;);'?C M/YX6DX'6,F<6C=4$+%M]YCSH)#<:AB((H5QA+L$SZ3(O>"(\SH"[@/JD7OY" M>MQ#(>$2)$8QP,#%7$#)!Y&GJ,^"2'I#(L%3D[VA;IDT"+K %+$#ER359?)# M(NA'@ (:IF4]L$[!$[;#[1R.ZTW9G-!)'SOKL,JLC12#6%+0YTYR*]Z9R?&! M[(U%K;\6F[DQ(2=W[#Y@Y-.A)F$Y]L(9+-F M[R?J:BPQ&/.!=ZQ#TKJX)7;5-*!B[$7-ND[=:K.M-EN]-LME;*!OY@![^_>7 MX!5 )]Y6E:V_*GN9-3)(IFU2CUDU6K;LC"K+'6P8*;*::<0UYPJY;5795I6M M7I7E<@-N!$.G#$^_ZU-_N'01U[W>G.OFK4I;B4J#V2L[F>E[TTVS:F[9WNGN MSJ;@XKI;%;=5<3^8BFN\HN+:4D9,;!7=ABNZ*BO7\!*Y611=4O>]VZ=_1%+Q MWO#CD7]0$8%HIO'>9>T#9!;K<>R1">;F*)H<:2:6-AU)+!*HV'PES#U&E)D- MPC0:K-H\K,&!LH69!1@QP4K/BBRZ4X?DMR=>K:.!>K6&ON2QN,H&YZ9T\+:S M^-2XTR>.1Z55Z1]\HJ^28]U:I%GJ8H"Q M?.IS>/-B45>9(+]NW##5<[=S:5*)9S*T[*Y6G?-MY2^#X31_-9:]-PV^+S#8 MG0JVG'9F;SC:VO8-I2?.K#*F\Y3=I&F3M?8<]\',Q%705.:GE>^HM*E MWR9R$5LTY(IZY)**!Z:6%Z5\([_I';TN/9[2]EV,GH$H#Z S\+T M ;.Q/"2.69"$ =GOT:>]%\&3ZF,()L3<)"J)RWK4?8R]5@ M5;*#)#S\I#,"TLI.PH19\33FYLL1(^B)GT7M3LNDG?F*Z/>8@+YX<77N6;DK&'TH MTQZHER;UGNA0)M?A?\Q4O+I\U>QL38*VOCM;<>6&<5#[^1,LEA4KX]@H54^" MAG/N7KRR_%_P^91IB>%+A:*=JL:U@$:QP5K!$PN$;9BVD3$A4Q8MWX7OW@7H MC$)N:B&_93+RE#Z]OI/4"L">8('QDG&I?>,W/>/9;.FA8=97 M:DZO$XMSF;WA=$_;G<0M =]51F"L*-@M/.PCP&I2L)34]\&T.3IG'ZCX8O-$ M0E>TE=C/MTC?QZ@IBQ>J$FU)'PN^P@O.K9]WN6*-!J&A396>ZTM_1DAE=Y#"[8]/8)@ MO'; MBUT><%3"0#(M*Z.MS'K! J5H*;&'4T$'>M;W2#"YE;PWNI?C"=PG(J/N'S!& M/&&,>)QVN1=WKP>D"C!S8J$<1QD]:*H74M ;()$BJ8^A.(F7B+BQ!.L$81BK MRS(W94 'X$"./FM"=$_#T9&37DY IFR0!X69W,GR+4^4=-4XH"ZX$PSPT7>5 M:/]'=X*7$FN4@EZ,$O P7GRJS]GI=T-RSWS08E[^O@_B 3P1?E$N04%&(.8UM-':1BF]4X?9?ZY7KR3DOED(QZ&QLR=V$=)U+9K05'1)J?[XZ[?QZ>W[W/;89UD:193_<&*=8 M?(NX2 )5LVX0%.1FN)$W) Z-,)]";US$'P9,(O42^ $*@OB+7UW6IUX/P]38 MD;9E204,F4<^M-'=T4CU P%D\C64MDW[>8RBZ] M03]C&4[?%"AS^X8QMR1ZMJE/S\R]8DFX80W"JDO7+?@YW>;X G!.7?MGI-N< M2Z1]XXWMG4VETR_#YIS\M&6H61BJ5C7P*Z>S;&V\1J7WW^B_&BJ1BJR0+^P1 MUMQWT4Q[%ULG^4_L)+^AD#<)?SQ2]@Y5NTDD^)@*G;I_MDDDVJK.K>KV>VNO,=NG.3*-#J<];+G Z)/W B5K2!NFW$R,[DWF603;TWMIRV(A"RN*5)#4'8\O_YV M@Y2LAQ]T+(LMH6=K'5OBH]$'W0<--!JO_^O=Y].S?WUY+WX]^_11?/GG3Q\_ MG(J]@\/#WQNGAX?OSM[E7S1K=5>M?7N-GYE\E _PW"[-(P2_!*+LX M4-][/???[1IK>.*@P.\ MH)\$U_#O7UZ/A3Q(XNQ@($=A='UT%HZ4%K^I*_$U&*8H+]TY>AZ-SH5/_S=[Y]=7X MS\:E;OWAIG7\SZW]9WR^)XQ&WNSM"1EE^$_1QJLPR(9';J\]_GX\S.5INO [ M//)P?/),RM@[^7O8)\@H/(^/4I3D^(?>66BUGT3!HQ'Y4?6__SX, M^V$F>KV:^XQZ6VG??"/P60\KUH?7J'1[-/M.I:,SY0_%5S5.TDR+GY-)F@W% M/R;26+&, _'S)(K$OY1,A5?W7/%S&,O8#V4$]^A)E.F[M?&?B<["P?7]ZG") MF3I^/FW+3]*_.$^321P<^$F4I$=_^_D]_@^N^_A6_._GCQ_?.N(4&CNHB;__ MK>NY[K'X)%/0I^N@MKSIIZ\/\;&+#U\!_9ZWB=L>4%QDW%!]#DQ'?(C]FGCU MV]MO[][^XTB\^W3V?_OB%8KBU8^G5YD_W>-]1T@1@1<'M,-8C%/EAQH(1, ' M(YG!*\ZOA8IE/U*!Z%_#Q: ]@.I2ZO!2"7T!-YVK.!F%OA;C2&:H84=D22"O M16IZ%=PXF'6:-.\T0FJ1#$S_@AM$-E3BC[D^-PBU#Q=?8Z]3T"T"\4[Y:M2' MKQNY:MW:5"7/U/WFD5G4]*:,\V%;_!5$C%#,P@B#\%*8MK_9B]0@VX./,D1. M]),4\'RS5]\3OHHB/99^&)_/_A[+()C^/55D?@OVQ$B.M3J:_G(L"E*K@Z;, M&U+\$8C+XLV@U27^:]2ZK9?'5\,P4P?X:E3&52K'>P\ =Z=!/(QH*;>P"&MI M9"*5 1X'A1*/9J\KN@3Z@WX:+G>%>?* $52P&TJ[K;\7>OCO)=OX[R=I>.]N MYWF_VP^4GZ02Q\3Y"U?U(R=94F&S[J*&DJ^'?H6>O'T\YP]O[U^D.LZS6]L# M1&Y O[6#W [),MG>"=N=@_*?0G"@Z(RU'(WAG\LDFHR48<'Q.$V^AT"W*KH6 MKNMTNO49+0YR%IBR(UR.KA]9N^F]!,KV4R6U$GXR&LL4B#)+EI[7=1KU.O"N MCPX]N/^Y]9JX0\S9;'^:M7OX,?[J.G MQ9>NLE+Q?"..Z][(@R]TVW>]D1EI-VR$&8D9B1G)6D8Z2S(SQ3C/2-XC&*G9 M^P%&6GSI@XS476"DNLN,M-,VPHS$C,2,9"TCO8UC$, 'GR[/4Z5&*LXT^%+@ MD7>S];509Y]C:%)DEGA^"I,/_T &4-_'^'>F(C54,H);DL% I: //6.9V?KM M)Q7)&-XISI3.F#>VOR\B=& M*@BAX4IHE5Z&OIHQAB&,A<2-?@AO2B],7H&,KG6HF36VOQ\S:S!K,&M8RQJG M4@\=X<-/H?Z8A( ,QAL.)MUE:>AC)I[Y$N,*/4Q24 ^PBS!$D'MQK?Q)&F8A M//A*I4J\\+QNK3F;0I.9"3L4W)\,S*\XQ56..=;?,>;^1"XZZM3:O9?KS91^ MNH!+XCPME7"-B:Y%.NCO2DC >1SA#&20AZ;))%V>[31)F8NI'V.5XDLDC%)$ MH/086,3T"'Q5,M$"MP9<0<.UP.G-+$\?Q0O,T&44^C7Q(2ZF7J^@YTWZ.@,1 M0PB$KP6F?\(=*(F?C$8JQ>111R3P4F-'T*G'\CI)'2-9H"Y5E(PQNH9X68YT M39P-0PRT0>(\>=4\2O;#*,RN,;KVY3B;I+G$XS09A1J'2;DEP&LP;W42YX: M=WZ#;S(8@H4^#)E>Z\EXU8\BET8P^#HH$OU=#^#&W1 AM*7H3L9'GGUZ?0A/ M.%G-FQ4P2 );U4H[17JNT#(,Q/\FPUB\2_KRPA&?WH&%#T,U@$$@&&N&@SD8 MYL%HSTPU3X>+>4)R#G"4)!DZ2:X0JOA'AS :D!2&YAR[>*K MD_1\.5X*Q23'' M7/C;,R.R8:J4&,$KAOJN+'=G85$(GM]>>8R6(X7..$R".](DM #;OA(OVO.+ M3W WYD/DXLUG2MS(=Z6BRT<*V+QEO>U6 <^&-XI#IR,75'HEP2FF(?0'0%<$ M\ D\? CXP9O[MR!2PUW0+Q]MN7Z>Z' M8C^""9&!!<#5X5 P'R5A.*I\PS9WID7>8(_9F"NYETNYG(]'_+94SGOUNB2G MGI,0\S%7'IGG:SX%\\7G>4VG?H>,Z"IP@V$Z=19C@.B@#])=',@!J/U(1E?R M6A\O1?^\8[#Z'8-K<.9DO/<]05>%4H$%/QP45BA?[EY(BW@*'Z?2SV8T0EK: M0!6.F;24M'7X@K1T-PD\),5KDI9N.HPD+:091I.6L-TB+5X1?Q"W%(^T=+0[ M8(FHE[3\T^B'M)"T5=@@+9WKD!:/-K00%9"6SR4MW=+D&6E9ZZ2EHSU^:).6 M[J$)6]+">[3[)7'Q:)L-[9ZW,MLTF] A'\]T24M'&_;Y!332@K9HNY[MB/R) M6\HRMOL?P":5%O4K%(BTE['I(V\]"V9-JZ$UL36C=[I,7+0VO2(M+V,0W: M9DQ[R6TK$G=H6P?G2E@+/8?]3PS[24M(77_;DXY &V?:XP?:O9"V?^9<"5O% M([[YA>?!UBTF;0)LU6A/0FS/; YM.J3M%&GK[B6G=C\A72,A+1[Q^,2E;1FT M Y3MR+JB+21IZ;8BBX#SU3A?C9*0M%7($]<\<FZ9&E;VO(Y5DO2Y 500WBA*>4K;M=#N;)P*)?K+FDB5N?2 M5"GU2FBDJ.!G*KG>J93%.K2W*^-FCEDN%6LTS_ G:8KOR&68UDN\]77E^\"L MI7>JX*%.<9\8Y2%HW?7Z1K<,!"M5&1?DP1>4*Z\BB\T<.(717SACDQI^#XQ)^!8Z,*^W5)I5WT?JU@K M_=CN;(I_NXU:8^ZXNOBF;P >;GNYF[]HU=QRU3_+25JRQQM1&YV;TJBKHC:6 MW?,+MUU6U@6;6"Q,*K,L#?N3O'1Z80WX%FA'WFVQ+VKHI9&I?UTX8'-XARYZ M-196SBLD@Q ^6,U,(;DMF"K70OH^%F%J4QGK1X?3LCYDB;VX+ MXT$J=99.?%/K.HPOP4#R,ZA EEFCY!6H)<87%'QPY[%2%AK55Z6!:OSA2J'Q M)UE6>^%DXL7>ZKF-E=Y:ZY7KK(^0]C'6!=9RMR/PZIU51]#X0>-:I)9;C"D9 M%*??8%?'YZ9W-1FMQ<&G1Y/9Q5.#P<=((,8K<6IJJ7_S0[@%JZ&+ST4Q=7Q< M_N4G/%8'3*SXQID;7/A1&)OOP!' 3R/BPO= :CGO.4(G@PPMS3P9.A](>@.+ M*5\\NTV/S1$+,0QL^GAR1))>"ST9CR.L1P_JP=^3-#,- )(%$LSFFUY[MEKJ MI$WU%W!BJ/?)YDK)V;HM:KU-+RECN_=U-F^_[._RAY'V.N M7G/AF-E%B;OU%>_2*"OQ/5RX:+C /RD,ZPZFU)?;KCEW)$O\BX-^81USYFUH MS80O89P_"XQUGN&6V$Q/T.:U&$Z@:\W.&P#KP_&H,3BX ;N&>7H&=!9#1SV_ M-E)$,"2.YF^2H-ESD60H?#;$0Q;MI+O?5 :!I'Z@B=;7JF1.Z1L4S*?+^#/@9R'9B(X*X^@H=^I,4)(JVSW,I6<[Z5]UC0J@KF3@PHI8+<6>!]-RTVLCVIQ36QBGL9AY,#W^G.CPY0 M)5ZMX]X'/'B<'VVV^^/-Y@+TQKUP ?J*?2S-V=\5IT!ZKOI>'TU:\@;M2@^T M,X-H5[/>BLP@A_82'@X?2 OHU5SBO9"T=+-1(6DI.7'XZ^&42!GCPMI6]\9., MY7F>(@;]SQP\"KUJ*+/BA.IIMIS1U-*YLL5QUGV572D5XPK$7 ^,%Y*!2A6>$'\JHWRA\W?5!U^1B0\WBW,/:V9[ M.^LLE<9TE6$"+9>XR#G5BS_5RU6A%Z#.(-3^!--]5C- ![/SM_.$.HU) F<3 MI0-Y[8A/)@\B]YS053/A'C7J8EP;U<07Z9OL!K 7)0Y%<_;%>WBI2F/S1;[ MNRR=+V/LXWD.$CCNR!PY?ZGR*&\\A-;C,ER 1\''Y^)5M]G<%\UVYZ#CNDVS MGO3/VK>:>99*-:X/O6K6>_O":[@'7KW;-I>$,4HABZ7>XEI'3#0^DI270L "EP&KL'8WECC:REBB%'?[/W[[?L/ MG__Y$9[P%1>Z4A5\ 0_S$RX,F6]<7/R0O'9D[]K10_YU4QYU87!\9WOV3M[V MDTDVR^,[JF#P6F7_+:FDF6\.-3CE2$F3)G:NXF04^CI?8(HQE5R@ZY#93?H( MW(!),'FZID+S'N?RC"&> K;6YMAB2?7NYUC#>,*;9XK*$YCT?"IB_A6.X$TVX2"2HU&>Y0?:KJ]I4CH*)2_JF MM3/HO -?H!$F^BTB^F?4]_P;2P\6O7RPN.: IK(1!SB:*YD&!U&27*#K^I:! M+S)[")XA;*O0%LZ&(::SJCRGK-@ 9=9:M$!_Z6$8N:@*/5.%N< ]-GQ;,,1( MR1@O*K94%(_08^A0&]];7/LE#2_AR>+;S:391_CG/'?O7Y6A M^;>^(1NWUVOE@1"F#/N9++AF-C-2;"-)D_\4>ZSR:;:"$$<2*6 TWR1"7L:-AIB.:5JM,6"]2TG"Y OC MV&@FQV!B4GEQ-B4#4OL]20,]2^PM5):WRYFJ:_IIT;[ESXN&+G_9+AG@9YRSOS'.O9YV;>-@2KDREV(S0"@Y TFX:R//D31WB! MV21QG4-T-]*F0][?%PK;,PPA,"QYQGIH]7_#"Z3 0V@%ON^VQ8QB1XC-GN\"F/6 V80E#M*ML MF/N$E=N+=1A$.M]B8]S!='])@EX"$^/G-]J G##"A@'@K+6EL+],,+=8 U?@ MI!2N J6AOLB?/,%1<2:AWX73>5UC)#!>GN@\NECR4&;*S/@P] AIGA]NW%DV M\XLJF%Y>$Y]P%B[WM2@H/ U4;CH[=$0-G7SJB,U>ZB1:\)BFDZ3*O#'TX8'X M^L($85A>/,R(C'YNXB6$WUG(I\G/R$,9_9OPEQP@1[@O$XB_+=VJ(YE;7O!P1M MU2EBR\)P"S]@I$#]7ZAKH2!63JZ5PB=V]HOE5FUV;^.&,=\H/))7IF6I.I\4 MD1Y\[3(I=@=#1,4HOK#?GL%>] M_>+NN]S)+'T&U//J^_[\T.PKW#*UWRDQZGS,-/4'(W0<,&1 <-_&,?J@K\IL MQ(-K?L91F5L_^#\Q"(O)G;G)_T(E34GT[?WIX4H M^[G/?G4];6&0^)/:O0]I)4*GWO?W]Z<(LQ*0_&]45MZ6F.?.S-># WS>R96YV*V^%%<_@UA5A,EX&CA670F?=5FSPOCXBPF-T0XL(9,1*9W[[]^.GM_^JLC/OQV^O B]'8# -&)!A\9F/GCGV1DXNYO0Z7N M6\7;[B:_,NMPR41#R(+K8=]-Z&]V'N93@M-]B#A_(/>?1PT_E'WPE]=!> D_ M\\SY?I*".W^S5]\3OHHBC<4/X_/9WV.UG\]_>#8&8EQ]$:I 9 M'4P_^&J:5J]U6G,?GJ&B\H_R-[?=6KW[\KAHXE2UIJ.*_,(\K0FW^@[3*.PNB].U7[ MO6YCC?H'0:#1 ("WMPDLIA_]=*/, IYVK>/=#]!46\]O'#3@6MD@5)7EE+>; MJV&8J0-TW-C@JU2.+3(E=F7LRMB5E7)E=79E9+!9,:7#?'3\\!#Y].>?ZS^? M/J,E%:-F0E9BYK^?#8J;*:Y?HXM>N^6Z3:^>SV:]U;J(8$N9S;-#8SBH,H-X M7A@>2>[/K^N7%GNCJG7?,F3^D/YWF+O)(<+6P%[?!EW3ZN>6*7\;W+YED%AM M#[<'9="NSIG4CYI=IUFLT<($S8) M]O_6:)L[._O_:C%I])R6Q_Z?C$GPRMBF5/_6]Y,)5MK$PJSA)89DA.8FF(=Y M)L@:]3,/GS2<;K-#"!*V"';_UFB;.SN[_XKS(IQFMWP=#[8($E$8+XT]7?58 M*3K&$RP)34$P^?*$CS7J9_(]>0SULCWLN#VP\^?.;HWZV?F?N/4F(4 LMX?- MKGX]O9KXC@5C7U(UEM!L/%XNUL59@_FQ@?Y"+8^-SU00J-5+!B5R\W?ERO-: M[=BJAJA5NHJRU8.!AN.VVU4Y-U+EE,E 4I$I,>%4#@$3SA9#Q(13ORJ=I:&?J?QH M-T*3$LS / 5DC?J9@4\:3MUK$8*$+8+=OS7:YL[.[G^[ C"V"1(!V+KBX T7 M42$.QF=3+*6B-3'>LTYXJH[WK).'B/>LE]NSWBY_4,&:71OO6"=D2$PWE4/ M=+/%$#'=,-UL(R"$JW8&R01/UO9JZR.>K:F:0JXRYS. L6V64?U,V(-[J^\# MS<9AP@M"\)7<'K\."'=Z".$UNTZCOOE]>W<-(^[TC#89&KG"GN7X:J<-A0EL M^S%D ML]NVSWG$X%YP,R?ST]#!Z%01"IZCEVJ0G=([%^S\F8;;KIPP2P8/<5.LB!UD_ M1""'S^HX@<< Y$&S/,VJ:O5SGBTS"./##++%H%G.(+Q32W[D2(T$\$DS/,^U2?D<,&XC=3P[CXBE8:-8<=]$7M^[NSL^:WP_*[3ZC0( M06*7,>SL\M=6!%[I! N%)J.QBK7,PB0F- '!%,S3/=:HGWGXI.6XWN8W,[!% M$+4(=O_-!F+X/6O38=A2F,C#WP4MBF5/]MF*1PK4I'(E #E:80 MCZ7J4L63\NF(/"6Z6W-RECN?JM7/9 RQ6*."\EYL$40M@MT_=W9KU,_N_Z17 MY_4P,O; ZV&;+LPQAI L3&*1#$0R5JG,0"$B4E(K7BHC8!!5:]MR?U2U^IF? M(3QKMGBVE"V"W3]W=MO4S^[_T2>#<,YQTNI5QVR",9>RK(FI+ M^H"(V65&Z3PZ/I66P-02GTI+'"(^E;9<2.BY9([CX5-IJS,DIIO*(6"ZV6*( MF&[*T0VATTN9;G9YV7!KSCOW5\OZ$YJAX3GBZD[G89:GAD_)9-YQFV$&809A?)A!'E-7J^F53R1E B$1$?*FOJ>K_G>9PG4WH6#Y8[YY M+\=N32=:[G*J5C\G"YVXS38A0-@>V/E;HVWN[.S\J]XHT&[Q/FXR%K$K:W+T M(["/"33\:555>$9UMV;L+/<]5:N?V9CW;52M?VHVP03 G=T:]3,!G+0;Y;,F MV1Y(!&.\'+;.8.S.;7D.?*3U+(>RV,E':.:"J9KGB:Q1/U/UB=O@93.V!W;^ MW-EM4S\[_Q//8^=/QAXVNVC&Q566\/A\=P5,"-JFD=W&IS5XGSOAJ3[>YTX> M(M[G7F[&UG&;W:J<&^]T)V1*3#B50\"$L\40,>&0SA%ARJ&[=KCAF'1K*J[\ M2*45KK-6.==LLL[:G1NS>;Q ',.2&^QY0/'00F;7:;M<&Y04)EP;U%8(F+-V M&4/FK#6=!>_TFIO?MLB417=9]OG29XGK_5N6^!?#)(+^J,W<4.=8J#\F879] M1&ARCQ.DN#8 CL;*S\)+%7%A7YIDSYMR M=ES]O$GMI$$(#K8&=OW6:)L[.[O^BO]/1I-(9BH02394J?"3T3A50Q7K\%*)*-&;WY?+ MS$Q#VY9[H:K5S\Q\\LKUFH00L/]KAH(JD0D.G& E_& M=$,>(J:;LA.+7:?N;?XH3Z:;M8:>7)[W>TEN.KG384)K#MQY );/?LLMUS.MWR MH;*5_%6UJ\PCY<-,@FK@LR"\//GK7UX/TQL4SM5!/U7RXD .,I4>R>A*7NNI MDNOUQ^X_65#-RX<;GZMIIJ>PVH^^%WB)% M+$?POG^_??_A\S\_2IU]5?#05 5?H(?\A!W$?--$)<@[7)P/0JCT81]WF\P% M\/TD"FZSID=TH1_M+^_>?_UT]O[T5T=\^.VTMH3#SK3R-(D-VYGD^F\9_#," M 4V-Z<]CE4HL4Z5WM?&OPEADPV2B91QH1ZCOO@*N,+6CS0S6K/JX /W(_>=1 M0PDJ,"K:F$NXYZ7(%\#KR!X%V[[9J^\)7T41\BDP\^SO@JG-W\4@(-?2S*\6 M= W01W*LU='TEV.QQ#;+$[O//IAHMFN=]M.7*LOVBH?'$PN@G<+3^VGXW'Q9 M<>CK;20#[79UEW%/1O'=,N.Y=0( @D"C 8'V7J5!D]>L-4HFV#Z_==" ZVR8 M*B4^P9=#+=Z#>,%"Z?WJXJ(-Q#LT$&"/11 ]EADX?J7DBDI3T4HV8$&0B4S M'>P;$!.%APFG>@!FA.-52SCNNO(H;;$F/)N*1\DV.:T?,HN-+GK3A8S=W):" MB2?OL9NSPS;K^J2Q5/E#XBM%'U64;*9#1.;E]P">*P*0^='#YU!H@V0'95P2:G?J8+ MI@O&A^EB6P!BNF"ZL$?=[(UHX\-T01P@I@NF"WO4S=Z(-CY,%\0!LIPN-EOW M[_F6C;;@"#:MY;5(\_4C0K5;F+ W7.G()G]#J4A1W?*34#VGU]Y\;3RV!**. MB/T^]W;V^Q;X?==IM1N$\+#+$L@Y(O;[W-O9[]O@]UVG[K'C9T_$CI][.SM^ M>QQ_T_&:F]^2R)9 8F?.TZL-[=BZRRE\G$H_>_32R[I/;JRRUA 9- BN__)! MC,0AJJ\'HYWF?+?7YA,6*0%2\3'!3#84/1F3#7F(F&P>!JW5XC/I20'"9&,M M!DPV6PP1D\W#H'7=%I,-)4"8;*S%@,EFBR%BLBF3*]=N-IEN*$%2\9:E#:^G M>9U:HT4;D+,DD]%T-4V3J+3*XP Z:_UKJ:IJM8.K&L,R>Y9Y)/$ J@W';9Y8"X92 B5!F?"HN+LF+"V'T,FK#6@ZCDN'V1!"Q(F+&LQ8,+:90R9L-8Q M5^LZW4;Y1!1FK-VU-&:LZC%@QMIE#)FQUI$WZ72[/"=("A(^1ZNJ77DZ$\E@ MMHS(YVD1I18N86P[/NLH8;S3M$X.,M?N8/Y@_&A_EC:Q%C_F#^L$?= MS!^T\6'^V#;$F#^8/^Q1-_,';7R8/[8-,;IWZ;7?^KM/N;3Z9G;H_ZK7?^ M=:?9+E]WBNUAQ^V!O3_W=GO4;[OW;SE=/J"7CCGP>5TDUF3\A,_MHH,*P35B MWC-,'"(N.%RBZE*'JPU3PH.+VUN+ 7/-%D/$7,-O^7*=WVS'D.KUK0+7AU)OEPU>NT[N[AL:$53T&3%B[C"$3UCH"8*?C<6%Y M4I P85F+ 1/6+F/(A+66Y4&G5<&&-V8L>I;&C%4]!LQ8NXPA,]8:4&TYO2X? MCTP*$KMV[FW!*N,O::*U&*?)(,P.7T7PQSXG')&RD*JS67@XL?T8\G!B'0'P M(^9K.65I=\V,Z:IZ#)BN=AE#IJMU9,3TVDQ7E !ANK(6 Z:K7<:0Z6HM^3!> MI_SJ(A/6[AH:$U;U&#!A[3*&3%AK0/45QU>T -E_]++BLZ_C/_D\-N(J_SQ6 MJ MV/MS;[='_;9[_Y;CUC>?QL[F0-0,]O#DY9?Z.\!HK_\\E5I)5-_:%9@ G6IHF0\ C$) M+44R%?/*KSWJMYV*6TZOM_G3P-@R!J#^S]N;?;HW[;O7_+\7H\]"=C#CM]N!/]99E? M5*Q2&9E5&1F,PCC4&99KNU1@R8;K88(J:;AT'SG&ZS?+#)=+.[=L1T4ST&3#=;#!'330FZ:3K= M!A\Y00H3YAMK,6"^V6*(F&]*U;'I>AS?D,*DXCU.&UYA\SJU1HLV(&=))B.1 MK!R#M/$U:!X24,[+X$,3MQ]#/C1Q'4%LVVEVRZ_1K=D[\J""D*4Q8U6/ 3/6 M+F/(C+4&5'M.M[WYK<1,6/0,C0FK>@R8L'890R:L=61!=IUVQV/&HH0),Y:U M&#!C[3*&S%AK0+71ONU9:?R8:"T&:3*:KC8FO*C[[.OZ3SV@CKO+/V5"E(HS]9*0.7Q6;%/>/""52<)UN:KE'-KDD MO M$!"WQ:Z?C8%=/_=VZ]1ON^MOEJ_DSK9 8L5EO<4>-U90D/XRS.E0QN=*A+$8 MR#!%_4^42 ;B2J9P?R:B4/;#*,RNN6HQ*;.I?IV8MPX3AXA/-RUS$!F7R"<% M")?(MQ8#)ILMAHC)ID09"M?Q6N5K)C'?D*J9Q%1C@Q]CJB$/$5--*:JI=YEJ M2&'"5,-^C*EFJR!BJBD7U7A,-:0P>7QM/3ZQZ[FP.$LR&8G$E-XK2NYQG=XM M8AFNT\L8S9P 6F]SC5Y*@%1D9DQ7U6/ =+7+&#)=K2GR;728L2AAPF>@ ML*-CLMHM#)FLUD%6/:8J6H@P5;&;8ZK:+0R9JM835[F/2%YALB*YHKB)+7M! M,NE'2G@UJU84?U.9B!*M*>43/0,2Q"V"7++*XZEG 30;QP\O",'W T.''\)O MMX<.7MNIMQIDLI'N=(LV61FIQ%%B8KDLB'] ML]6(J_QW\R@5"'FI4GFNA!Y"O],BF60ZDS$J14PT?!_&",Z.:B&GZ-6??C(: M3S+405RLHHJQ2G,=.:(O=>@+4)((PF@"2B246L(ERBO,QK)^N$0.G_H: -KI M\9#7H10L[S8>=7J9PYA#F%\F$-*GY'4<]K=CM.K;SX;ESF$J-$P MAS"',#[,(:7CD*[3[3:=;H?/V&:C80YA#F%\F$,>&X>TG5ZGYS1=/K*5C-%L M=A>@M*"SX3PHFUPR ML10FJT6C6KW0R)?WMF+1 ?:3X/KDK_#F83:*X)?_!U!+ 0(4 Q0 ( +: 852+ MW"QONP0 %H6 1 " 0 !D;71K+3(P,C(P,S Q+GAS M9%!+ 0(4 Q0 ( +: 850\QW08,P< %9, 5 " >H$ M !D;71K+3(P,C(P,S Q7VQA8BYX;6Q02P$"% ,4 " "V@&%4QD*%4@H% M !K+0 %0 @ %0# 9&UT:RTR,#(R,#,P,5]P&UL M4$L! A0#% @ MH!A5".Q>3^/$0 +IT !0 ( !C1$ M &1M=&LM.&M?,C R,C S,#$N:'1M4$L! A0#% @ MH!A5$/\?=P#+@ M ST% ! ( !3B, &1M=&LM97@Y.3%?-BYH=&U02P4& / 4 !0!% 0 ?U$ end